0001628280-16-018725.txt : 20160808 0001628280-16-018725.hdr.sgml : 20160808 20160808172444 ACCESSION NUMBER: 0001628280-16-018725 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160808 DATE AS OF CHANGE: 20160808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 161815283 BUSINESS ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 BUSINESS PHONE: 303-863-8088 MAIL ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 FORMER COMPANY: FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 10-Q 1 axdx-063016x10q.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-31822
ACCELERATE DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
84-1072256
(State or other jurisdiction
(I.R.S. Employer Identification No.)
of incorporation or organization)
 
 
 
3950 South Country Club, Suite 470
 
Tucson, Arizona
85714
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
(520) 365-3100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ  Yes o  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). þ  Yes o  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
 
o
Accelerated filer
 
þ
Non-accelerated file
 
o (Do not check if a smaller reporting company)
Smaller reporting company
 
o

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o  Yes  þ  No

As of August 4, 2016 there were 51,228,452 shares of the registrant’s common stock outstanding.



TABLE OF CONTENTS 


2


PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEET
(in thousands, except share data)
 
Unaudited
Audited
 
June 30,
December 31,
 
2016
2015
ASSETS
Current assets:
 

 

Cash and cash equivalents
$
37,519

$
120,585

Investments
64,919

11,839

Trade accounts receivable
169

77

Prepaid expenses
1,564

1,638

Other current assets
1,232

12

Total current assets
105,403

134,151

Property and equipment, net
4,960

5,016

Intellectual property, net
152

157

Total assets
$
110,515

$
139,324

 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 

 

Accounts payable
$
1,789

$
2,623

Accrued liabilities
2,642

2,543

Deferred revenue and income
43

127

Capital lease obligations
—

13

Total current liabilities
4,474

5,306

Long-term deferred income
1,000

1,000

Total liabilities
5,474

6,306

 
 
 
Commitments and contingencies see Note 11, Commitments
—

—

 
 
 
Stockholders' equity:
 

 

Common stock, $0.001 par value;
 

 

75,000,000 common shares authorized with 51,218,417 shares issued and outstanding on June 30, 2016 and 55,000,000 authorized with 51,191,184 shares issued and outstanding on December 31, 2015
51

51

5,000,000 preferred shares authorized and none outstanding as of June 30, 2016 and December 31, 2015
—

—

Contributed capital
248,776

243,894

Accumulated deficit
(143,855
)
(110,915
)
Accumulated other comprehensive gain (loss)
69

(12
)
Total stockholders' equity
105,041

133,018

Total liabilities and stockholders' equity
$
110,515

$
139,324

See accompanying notes to financial statements.

3


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
(in thousands, except per share data)
 
Three Months Ended
 
Six Months Ended
 
June 30,
June 30,
 
June 30,
June 30,
 
2016
2015
 
2016
2015
Revenues:
 

 

 
 
 
Product sales
$
—

$
—

 
$
143

$
—

Licensing and royalty revenues
20

19

 
40

33

Total revenues
20

19

 
183

33

 
 
 
 
 
 
Costs and expenses:
 

 

 
 
 
Research and development
8,062

7,126

 
15,416

12,856

Sales, general and administrative
9,239

4,755

 
16,676

7,622

Amortization
3

3

 
5

5

Depreciation
605

403

 
1,147

729

Total costs and expenses
17,909

12,287

 
33,244

21,212

 
 
 
 
 
 
Loss from operations
(17,889
)
(12,268
)
 
(33,061
)
(21,179
)
 
 
 
 
 
 
Interest expense and other
—

(2
)
 
—

(3
)
Foreign currency exchange loss
(117
)
—

 
(73
)
—

Interest and dividend income
140

18

 
194

33

Total other income
23

16

 
121

30

 
 
 
 
 
 
Net loss
$
(17,866
)
$
(12,252
)
 
$
(32,940
)
$
(21,149
)
 
 
 
 
 
 
Basic and diluted net loss per share
$
(0.35
)
$
(0.27
)
 
$
(0.64
)
$
(0.47
)
Weighted average shares outstanding
51,213

44,678

 
51,205

44,664

 
 
 
 
 
 
Other comprehensive loss:
 

 

 
 
 
Net loss
$
(17,866
)
$
(12,252
)
 
$
(32,940
)
$
(21,149
)
Net unrealized gain (loss) on available-for-sale investments
29

(8
)
 
81

(4
)
Foreign currency translation adjustment
49

—

 
—

—

Comprehensive loss
$
(17,788
)
$
(12,260
)
 
$
(32,859
)
$
(21,153
)

See accompanying notes to financial statements.


4


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENT OF CASH FLOWS
Unaudited
(in thousands)
 
Six Months Ended
 
June 30,
June 30,
 
2016
2015
Cash flows from operating activities:
 
 
Net loss
$
(32,940
)
$
(21,149
)
Adjustments to reconcile net loss to net cash used in operating activities:
 

 

Depreciation
1,147

729

Amortization of intangible assets
5

5

Amortization of investment discount
123

99

Equity-based compensation
3,921

4,185

(Increase) decrease in assets:
 

 

Accounts receivable
(92
)
(65
)
Prepaid expense and other
272

(675
)
Other current assets
(1,220
)
—

Increase (decrease) in liabilities:
 

 

Accounts payable
(394
)
(129
)
Accrued liabilities
1,175

657

Deferred revenue and income
(84
)
(14
)
Net cash used in operating activities
(28,087
)
(16,357
)
Cash flows from investing activities:
 
 
Purchases of equipment
(2,084
)
(2,160
)
Purchases of available-for-sale securities
(63,534
)
(8,017
)
Sales of available-for-sale securities
1,000

141

Maturity of available-for-sale securities
9,380

7,807

Net cash used in investing activities
(55,238
)
(2,229
)
Cash flows from financing activities:
 
 
Exercise of options
95

327

Common stock issuance costs
(814
)
—

Payments on capital lease obligations
(13
)
(73
)
Recovery of related party short-swing profits
991

—

Net cash provided by financing activities
259

254

 
 
 
Decrease in cash and cash equivalents
(83,066
)
(18,332
)
Cash and cash equivalents, beginning of period
120,585

53,563

Cash and cash equivalents, end of period
$
37,519

$
35,231


See accompanying notes to financial statements.


5


ACCELERATE DIAGNOSTICS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or “the Company”) is an in vitro diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC on March 9, 2016.

The condensed consolidated balance sheet as of December 31, 2015 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2016 or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. During the three months ended June 30, 2016 new entities were formed based in Europe.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt

6


securities, certificates of deposit, and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.

Reclassification

Certain prior year amounts have been reclassified for consistency with the current year presentation.

Inventory

The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (“FDA”) or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the de novo request being granted by the U.S. FDA. Accordingly, the Company does not capitalize pre-launch inventory prior to receipt of marketing authorization, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted. Costs associated with the Company’s purchase of inventory are either reported as research and development costs, or if the inventory is used in marketing evaluations, as sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.

Revenue

The Company recognizes revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.

Deferred revenue represents amounts received but not yet earned under existing agreements.

Revenue from operations includes product sales, principally of ACCELERATE PHENO™ systems (formerly referred to as Accelerate ID/AST systems). When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return.

Warranty

A limited warranty of less than a year is covered under selected contracts. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in sales, general and administrative on the condensed consolidated statements of operations and comprehensive loss.

Foreign Currency Translation and Foreign Currency Transactions

The Company follows ASC 830 "Foreign Currency Matters," which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency

7


financial statements into U.S. dollars are included in the foreign currency translation adjustment, within the condensed consolidated statements of operations and comprehensive loss.

The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain or loss, within the condensed consolidated statements of operations and comprehensive loss.

NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an "incurred loss" methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020 with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for us on January 1, 2017 with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements and plan to adopt on the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019 with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation. We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers Deferral of the Effective Date, which deferred the effective date resulting in a new effective date of January 1, 2018 for us. We are permitted to adopt early but not before the original effective date of January 1, 2017. FASB has issued several other ASU's which provide further guidance on Topic 606 and have the same effective date. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. We are currently evaluating the transition method and the adoption date that will be elected. We will implement ASU 2014-09 and all relevant subsequently issued ASU's on Topic 606 concurrently.


8


NOTE 3. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at June 30, 2016 and December 31, 2015.

 
June 30, 2016
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
36,121

$
1,398

$
—

$
37,519

Investments:
 
 
 
 
Certificates of deposit
6,028

—

—

6,028

US Treasury securities
15,822

—

—

15,822

US Agency securities
—

4,010

—

4,010

Commercial Paper
—

499

—

499

Asset-backed securities
—

7,095

—

7,095

Corporate notes and bonds
—

31,465

—

31,465

Total investments
21,850

43,069

—

64,919

Total assets measured at fair value
$
57,971

$
44,467

$
—

$
102,438


 
December 31, 2015
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)  
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
120,585

$
—

$
—

$
120,585

Investments:
 
 
 
 
Asset-backed securities
—

2,507

—

2,507

Corporate notes and bonds
—

9,332

—

9,332

Total investments
—

11,839

—

11,839

Total assets measured at fair value
$
120,585

$
11,839

$
—

$
132,424


Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts, money market funds, certificates of deposit and U.S. Treasury securities as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no transfers between levels during the six month period ended June 30, 2016.

NOTE 4. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of

9


cash equivalents, investments and accounts receivable, including receivables from major customers.

The Company’s main financial institution for banking operations held 70% and 100% of the Company’s cash and cash equivalents as of June 30, 2016 and December 31, 2015, respectively.

The Company extends credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At June 30, 2016 and December 31, 2015, $129,000 or 76% and $50,000 or 66%, respectively, of the Company’s outstanding receivable balance was with Denver Health Medical Center (“Denver Health”). See Note 7, License Agreements and Grants for more information.

Revenue from product sales purchased from Denver Health represented 100% and 0% for the six months ended June 30, 2016 and 2015 respectively. There were no product sales for the three months ended June 30, 2016 and 2015.

NOTE 5. INVESTMENTS

The following tables summarize the Company’s available-for-sale investments at June 30, 2016 and December 31, 2015:

AVAILABLE-FOR-SALE INVESTMENTS
June 30, 2016
(in thousands)
 
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit
$
6,028

$
—

$
—

$
6,028

US Treasury securities
15,780

42

—

15,822

US Agency securities
4,009

1

—

4,010

Commercial paper
499

—

—

499

Asset-backed securities
7,084

11

—

7,095

Corporate notes and bonds
31,449

27

(11
)
31,465

Total
$
64,849

$
81

$
(11
)
$
64,919


AVAILABLE-FOR-SALE INVESTMENTS
December 31, 2015
(in thousands)
 
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Asset-backed securities
$
2,510

$
—

$
(3
)
$
2,507

Corporate notes and bonds
9,341

1

(10
)
9,332

Total
$
11,851

$
1

$
(13
)
$
11,839


The following table summarizes the maturities of the Company’s available-for-sale securities at June 30, 2016 and December 31, 2015:


10


AVAILABLE-FOR-SALE INVESTMENT MATURITIES
(in thousands)
 
June 30, 2016
December 31, 2015
 
Amortized
Cost
Fair Value
Amortized
Cost
Fair Value
Due in less than 1 year
$
27,517

$
27,535

$
11,851

$
11,839

Due in 1-5 years
37,332

37,384

—

—

Due in 6-10 years
—

—

—

—

Total
$
64,849

$
64,919

$
11,851

$
11,839


Proceeds from sales of marketable securities (including principal paydowns), for the three months ended June 30, 2016 and 2015 were $500,000 and $34,000, respectively, and for the for the six months ended June 30, 2016 and 2015 were $1,000,000 and $141,000, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no gross realized gains or losses from sales of marketable securities for the three months ended and six months ended June 30, 2016 and 2015.

No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of June 30, 2016 and there have been no other indicators of impairment. The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.

Additional information regarding the fair value of our financial instruments is included in Note 3, Fair Value of Financial Instruments.

NOTE 6. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost and consisted of the following at June 30, 2016 and December 31, 2015.
 
PROPERTY AND EQUIPMENT
(in thousands)
 
June 30,
December 31,
 
2016
2015
Computer equipment
$
2,173

$
1,877

Technical equipment
2,329

1,806

Facilities
3,491

1,772

Capital projects in progress
736

2,183

Total property and equipment
$
8,729

$
7,638

Accumulated depreciation - other
(3,769
)
(2,622
)
Net property and equipment
$
4,960

$
5,016


Depreciation expense (which includes amortization of capital lease assets) for the three months ended June 30, 2016 and 2015 was $605,000 and $403,000, respectively, and for the six months ended June 30, 2016 and 2015 was $1,147,000 and $729,000, respectively.

NOTE 7. LICENSE AGREEMENTS AND GRANTS

Defense Medical Research and Development Program

In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (“DMRDP”) recommended $2.0 million of funding for a proposed 35-month project. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections. The project will apply the ACCELERATE PHENO™ system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of $602,000

11


under this grant which is recorded as an offset to research and development expenses. The amounts invoiced for the three months ended June 30, 2016 and 2015 were $44,000 and $68,000, respectively, and for the six months ended June 30, 2016 and 2015 was $44,000 were $136,000, respectively. The period of performance of this grant was extended through September 2016.

National Institute of Health Grant

In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood. In June 2015, the Company executed a subaward agreement with Denver Health for the services provided as part of this grant which covered the period of February 15, 2015 through January 31, 2016 and totaled $689,000. The amounts invoiced for the three months ended June 30, 2016 and 2015 were $50,000 and $0, respectively, and for the six months ended June 30, 2016 and 2015 were $59,000 and $0, respectively. Amounts invoiced under this grant are recorded as an offset to research and development expenses.

Arizona Commerce Authority

In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1.0 million (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:

•
Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).

•
Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).

•
Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).

•
Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4.5 million.

For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of June 30, 2016, the Company has collected all of the $1.0 million in milestones. The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in Note 8, Deferred Revenue and Income.

Arizona R&D Refundable Tax Credit Program

The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”), which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&D Refundable Tax Credit Program"). The amounts incurred under this program are recorded as an offset to research and development expenses, and for the six months ended June 30, 2016 and 2015 were $1.2 million and $647,000, respectively, and no amounts were incurred for the three months ended June 30, 2016 and 2015. The refund for the 2014 tax year has been received and the amount for the 2015 tax year remains outstanding and is recorded as other current assets on the Condensed Consolidated Balance Sheets. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.

NOTE 8. DEFERRED REVENUE AND INCOME

12



Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of June 30, 2016 and December 31, 2015 follows:
Deferred Revenue and Income
(in thousands)

June 30,
December 31,

2016
2015
Fisher agreement
$
—

$
13

Products not yet delivered
43

114

Total current deferred revenue and income
$
43

$
127






Arizona Commerce Authority grant
$
1,000

$
1,000

Total long-term deferred income
$
1,000

$
1,000


We have received $1.0 million in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in Note 7, License Agreements and Grants. As of June 30, 2016, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the “claw-back” provisions under the Grant Agreement expire in January 2018.

NOTE 9. EARNINGS PER SHARE

The financial statements show basic and diluted loss per share.

The Company’s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our common stock to be antidilutive. As of June 30, 2016, and December 31, 2015, there were common stock options, restricted stock units and warrants exercisable for 7,529,452 and 6,778,580 shares of common stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.

NOTE 10. EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION

The following table summarizes option activity under all plans during the six-month period ending June 30, 2016:

Stock Option Activity
 
Number of Shares
Weighted Average Exercise Price per Share
Options outstanding January 1, 2016
6,167,170

6.91

Granted
899,600

13.09

Forfeited
(119,706
)
20.06

Exercised
(27,233
)
3.49

Expired
(1,789
)
13.49

Options Outstanding June 30, 2016
6,918,042

7.49


The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:


13


Black-Scholes Assumptions for Options Granted
 
Three Months Ended
 
June 30, 2016
June 30, 2015
Expected term (in years)
6.2
6.4
Volatility
85%
92%
Expected dividends
—
—
Risk free interest rates
1.45%
1.73%
Weighted average fair value
$9.66
$17.55

The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of June 30, 2016:

Stock Option Supplemental Information
 
Options
Outstanding
Options
Exercisable
Options Vested and Expected to Vest
Number of options
6,918,042

4,268,778

6,715,032

Weighted average remaining contractual term (in years)
7.06

6.41

7.00

Weighted average exercise price
$
7.49

$
5.01

$
7.28

Weighted average fair value
$
5.80

$
3.77

$
5.63

Aggregate intrinsic value (in thousands)
$
37,775

$
34,813

$
38,171


The following table summarizes restricted stock unit activity during the six-month period ending June 30, 2016:

Restricted Stock Unit (RSU) Activity
 
Number of Shares
Weighted Average Grant Date Fair Value per Share
RSUs Outstanding January 1, 2016
40,250

20.91

Granted
—

—

Forfeited
—

—

Vested/released
—

—

RSUs outstanding June 30, 2016
40,250

20.91


The expense recognized on Company’s Statements of Operations and Comprehensive Loss related to options is summarized below:

Equity-Based Compensation Expenses
(in thousands)
 
Three Months Ended
Six Months Ended
 
6/30/2016
6/30/2015
6/30/2016
6/30/2015
Research and development
$
462

$
747

$
664

$
1,435

Sales, general and administrative
1,773

1,781

3,257

2,750

Equity-based compensation expense
$
2,235

$
2,528

$
3,921

$
4,185


As of June 30, 2016, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock units was $12.4 million and $482,000 respectively. This is expected to be recognized over the years 2016 through 2021.

NOTE 11. COMMITMENTS


14


Leases

The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona and Europe, the last of which expires in 2018. Total rent expense, including common area charges was $280,000 and $167,000 for the three months ended June 30, 2016 and 2015, respectively, and for the six months ended June 30, 2016 and 2015 was $540,000 and $282,000, respectively. Future minimum lease payments under operating lease agreements are as follows:

Operating Lease Obligations
(in thousands)
Year ending December 31:
 
2016
$
498

2017
173

2018
4

2019
—

Thereafter
—

Total operating lease obligations
$
675


Clinical Trial Agreements

The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. The Company incurred clinical trial expense of $760,000 and $178,000 for the three months ended June 30, 2016 and 2015, respectively, and $1,424,000 and $358,000 for the six months ended June 30, 2016 and 2015, respectively. The expense incurred as part of the clinical trial is included in research and development on the condensed consolidated statements of operations and comprehensive loss.

Legal Matters

On March 19, 2015, a putative securities class action lawsuit was filed against Accelerate Diagnostics, Inc., Lawrence Mehren, and Steve Reichling, Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504. The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System. Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015. On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class. On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud. Plaintiff sought certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order. Defendants moved to dismiss the amended complaint on July 21, 2015. The Court granted the motion and dismissed the case with prejudice on January 28, 2016. On February 26, 2016, Plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit, which challenges the dismissal of the amended complaint. Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016). The appeal is pending; Plaintiff filed her Brief on Appeal on June 6, 2016.
NOTE 12. SEGMENTS

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in one operating segment because the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.

NOTE 13. RELATED PARTY TRANSACTIONS

15



In June 2016, the Company recorded a net amount of $866,000 related to the recovery of short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended.  The Company recognized these related party proceeds as an increase to contributed capital on the condensed consolidated balance sheet.

NOTE 14. SUBSEQUENT EVENTS

As Defendants in the securities litigation now pending before the United States Court of Appeals for the Ninth Circuit (Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016)), we filed our answering brief with the Court on August 3, 2016. Should Plaintiff choose to file an optional reply brief, that brief will be due on August 22, 2016, unless Plaintiff requests - and the Court grants - an extension of time.

Additional information regarding this litigation is included in Note 11, Commitments.


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introductory Note

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to the "Company," "Accelerate," "we," "us" or "our" are references to the combined business of Accelerate Diagnostics, Inc.

The ACCELERATE PHENO™ system, is also referred to as the "ID/AST System" or "Accelerate ID/AST System".

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company, intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as “may,” “will,” “expect,” “anticipate,” “estimate,” or “continue,” or variations thereon or comparable terminology, include the plans and objectives of management for future operations, including plans and objectives relating to the products and future economic performance of the Company. In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements are based on assumptions that the Company will retain key management personnel, the Company will be successful in the development of the ACCELERATE PHENO™ system, the Company will obtain sufficient capital to complete the development and required clinical trials of the ACCELERATE PHENO™ system, the Company will be able to protect its intellectual property, the Company’s ability to respond to technological change, that the Company will accurately anticipate market demand for the Company’s products and that there will be no material adverse change in the Company’s operations or business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) summarizes the significant factors affecting our results of operations, liquidity, capital resources and

16


contractual obligations. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere herein. Certain information contained in the discussion and analysis set forth below and elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. The Company’s future operating results may be affected by various trends and factors which are beyond the Company’s control. These include, among other factors, general public perception of issues and solutions, and other uncertain business conditions that may affect the Company’s business. The Company cautions the reader that a number of important factors discussed herein, and in other reports, filed with the SEC including but not limited to the risks in the section entitled “Risk Factors” in its Annual Report on Form 10-K for the period ended December 31, 2015 could affect the Company’s actual results and cause actual results to differ materially from those discussed in forward-looking statements.

Our MD&A is composed of the following sections: Overview, Changes in Results of Operations, Capital Resources and Liquidity and Off-Balance Sheet Arrangements. All amounts have been rounded to the nearest thousand unless otherwise indicated.

Overview

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of these results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these challenges by delivering significantly faster and accurate testing of infectious pathogens in various patient sample types.

Since 2004, we have focused our efforts on the development of an innovative rapid diagnostic platform, the ACCELERATE PHENO™ system, intended for the rapid diagnosis of infectious pathogens. Our goal is to reduce the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to hours rather than the two to three days now required to deliver identification and susceptibility results.

The ID/AST System utilizes genotypic technology to identify, or ID, infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing, or AST, which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST blood culture assay kit, which we refer to as the ACCELERATE PHENOTEST™ BC kit, is being investigated for its ability to provide ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Blood Culture Assay Kit is a highly multiplexed panel targeting more than 150 individual assays which have the potential to support clinicians in prescribing optimal antibiotic therapy for patients in this critical condition. The final number of assays included in the Blood Culture Assay Kit will depend on the results of our clinical trials to support marketing authorization from the FDA and FDA review of each individual assay for marketing clearance. This panel is designed to cover over 80% of the routine and significant pathogens causing blood stream infections and over 90% of the antibiotics useful in treating those pathogens. On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79 EC and applied a CE Mark to the Accelerate ID/AST System and the Blood Culture Assay Kit for in vitro diagnostic use.

On July 11, 2016 Accelerate submitted to the FDA a De Novo request for pre market authorization of its Accelerate Pheno system and Accelerate PhenoTest BC kit based on a clinical study representing over 1,800 samples across 13 sites. We anticipate commercializing the Accelerate ID/AST System in the United States, subject to clearance by the U.S. Food and Drug Administration (“FDA”), which could occur as early as the third quarter of 2016.

Changes in Results of Operations: three months ended June 30, 2016 compared to three months ended June 30, 2015

During the three months ended June 30, 2016, total revenues were $20,000 as compared to $19,000 during the three months ended June 30, 2015, an increase of $1,000 or 5%. The increase was due to revenue associated with license agreements.


17


Research and development expenses for the three months ended June 30, 2016 were $8,062,000 as compared to $7,126,000 during the three months ended June 30, 2015, an increase of $936,000 or 13%. The increase was primarily the result of increasing employee headcount, clinical trial fees, and increased purchases of laboratory and instrument engineering supplies to support research and development as well as pre-launch efforts. Research and development expenses include non-cash equity-based compensation for the three months ended June 30, 2016 and 2015 of $462,000 and $747,000, respectively, which decreased $285,000. We do not capitalize our inventory prior to FDA approval in accordance with U.S. GAAP, accordingly instruments and consumables charged to research and development were $1,647,000 and $981,000 for three months ended June 30, 2016 and 2015, respectively.

During the three months ended June 30, 2016, sales, general and administrative expenses were $9,239,000 as compared to $4,755,000 during the three months ended June 30, 2015, an increase of $4,484,000 or 94%. The increase was primarily driven by salaries and related expenses as we ramp up our sales and marketing operations globally. Sales, general and administrative expenses include non-cash equity-based compensation for the three months ended June 30, 2016 and 2015 of $1,773,000 and $1,781,000, respectively, which decreased $8,000. We do not capitalize our internally developed instruments prior to FDA approval in accordance with U.S. GAAP at which time we believe the costs will be recoverable and, therefore, sales, general and administrative expenses include demonstration instruments as expense totaling $748,000 and $260,000 for the three months ended June 30, 2016 and 2015, respectively.

Depreciation for the three months ended June 30, 2016 was $605,000 as compared to $403,000 during the three months ended June 30, 2015, an increase of $202,000 or 50%. The increased depreciation was the result of purchases of equipment and leasehold improvements to support the Company’s Tucson facility laboratory, manufacturing and administrative space.

As a result of the above factors, loss from operations for the three months ended June 30, 2016 was $17,889,000 as compared to the loss of $12,268,000 during the three months ended June 30, 2015, an increase in loss from operations of $5,621,000 or 46%. Loss from operations include non-cash equity-based compensation for the three months ended June 30, 2016 and 2015 of $2,235,000 and $2,528,000, respectively, which decreased $293,000. This loss and further losses are anticipated and was the result of our continued investments in research and development, expanded laboratory and operational space, increased employee headcount and other factors as we develop and commercialize the Company’s products.

Other non-operating income during the three months ended June 30, 2016 was $23,000 as compared to $16,000 during the three months ended June 30, 2015, an increase of $7,000 or 44%. This change was due to an increase in investment income.

As a result of these factors, net loss for the three months ended June 30, 2016 was $17,866,000 as compared to a net loss of $12,252,000 during the three months ended June 30, 2015, an increase in net loss of $5,614,000 or 46%.

Unrealized gain on available-for-sale investments for the three months ended June 30, 2016 was $29,000 as compared to an unrealized loss of $8,000 during the three months ended June 30, 2015.

Foreign currency translation adjustment gain for the three months ended June 30, 2016 was $49,000 as compared to $0 during the three months ended June 30, 2015. The resulting comprehensive losses were $17,788,000 and $12,260,000 for the three months ended June 30, 2016 and 2015, respectively.

Changes in Results of Operations: six months ended June 30, 2016 compared to six months ended June 30, 2015

During the six months ended June 30, 2016, total revenues were $183,000 as compared to $33,000 during the six months ended June 30, 2015, an increase of 150,000 or 455%. The increase was due to sales of ACCELERATE PHENO™ systems (Research Use Only) in 2016. The Company does not currently capitalize pre-launch inventory and the cost of product sales is reported as research and development costs on the condensed consolidated statements of operations and comprehensive loss.

Research and development expenses for the six months ended June 30, 2016 were $15,416,000 as compared to $12,856,000 during the six months ended June 30, 2015, an increase of $2,560,000 or 20%. The increase was

18


primarily the result of increasing employee headcount, clinical trial fees, and increased purchases of laboratory and instrument engineering supplies to support research and development as well as pre-launch efforts. Research and development expenses include non-cash equity-based compensation for the six months ended June 30, 2016 and 2015 of $664,000 and $1,435,000, respectively, which decreased $771,000. We do not capitalize our inventory prior to FDA approval in accordance with U.S. GAAP, accordingly instruments and consumables charged to research and development were $3,102,000 and $2,211,000 for six months ended June 30, 2016 and 2015, respectively.

During the six months ended June 30, 2016, sales, general and administrative expenses were $16,676,000 as compared to $7,622,000 during the six months ended June 30, 2015, an increase of $9,054,000 or 119%. The increase was primarily driven by salaries and related expenses as we ramp up our sales and marketing operations globally. Sales, general and administrative expenses include non-cash equity-based compensation for the six months ended June 30, 2016 and 2015 of $3,257,000 and $2,750,000, respectively, which increased $507,000. We do not capitalize our internally developed instruments prior to FDA approval in accordance with U.S. GAAP at which time we believe the costs will be recoverable and, therefore, sales, general and administrative expenses include demonstration instruments as expense totaling $1,336,000 and $329,000 for six months ended June 30, 2016 and 2015, respectively.

Depreciation for the six months ended June 30, 2016 was $1,147,000 as compared to $729,000 during the six months ended June 30, 2015, an increase of $418,000 or 57%. The increased depreciation was the result of purchases of equipment and leasehold improvements to support the Company’s Tucson facility laboratory, manufacturing and administrative space.

As a result of the above factors, loss from operations for the six months ended June 30, 2016 was $33,061,000 as compared to the loss of $21,179,000 during the six months ended June 30, 2015, an increase in loss from operations of $11,882,000 or 56%. Loss from operations include non-cash equity-based compensation for the six months ended June 30, 2016 and 2015 of $3,921,000 and $4,185,000, respectively, which decreased $264,000. This loss and further losses are anticipated and was the result of our continued investments in research and development, expanded laboratory and operational space, increased employee headcount and other factors as we develop and commercialize the Company’s products.

Other non-operating income during the six months ended June 30, 2016 was $121,000 as compared to $30,000 during the six months ended June 30, 2015, an increase of $91,000 or 303%. This change was due to an increase in investment income.

As a result of these factors, net loss for the six months ended June 30, 2016 was $32,940,000 as compared to a net loss of $21,149,000 during the six months ended June 30, 2015, an increase in net loss of $11,791,000 or 56%.

Unrealized gain on available-for-sale investments for the six months ended June 30, 2016 was $81,000 as compared to an unrealized loss of $4,000 during the six months ended June 30, 2015.

The resulting comprehensive losses were $32,859,000 and $21,153,000 for the six months ended June 30, 2016 and 2015, respectively.

Capital Resources and Liquidity

Our primary source of liquidity has been from sales of shares of common stock. As of June 30, 2016, the Company had $102.4 million in cash and cash equivalents and available-for-sale securities, a decrease of $30.0 million from $132.4 million at December 31, 2015. The primary reason for the change in these assets was the funding of operational losses.

The Company is subject to a Lease Agreement with Pima County of Arizona. The future minimum lease payments under the Lease Agreement are included in Item 1, Note 11, Commitments.

As of June 30, 2016, management believes that current cash balances will be more than sufficient to fund our capital and liquidity needs for the next twelve months.


19


The following summarizes selected items in the Company’s consolidated statements of cash flows for the six months ended June 30, 2016 and June 30, 2015:

Cash Flow Summary
(in thousands)
 
Six Months Ended
 
 
June 30,
June 30,
Increase (Decrease)
 
2016
2015
Net cash used in operating activities
$
(28,087
)
$
(16,357
)
$
(11,730
)
Net cash used in investing activities
(55,238
)
(2,229
)
(53,009
)
Net cash provided by financing activities
259

254

5


The net cash used in operating activities was $28.1 million and $16.4 million for the six months ended June 30, 2016 and 2015, respectively and was primarily comprised of the net loss from the statements of operations and comprehensive loss.

The net cash used in investing activities was $55.2 million and $2.2 million for the six months ended June 30, 2016 and 2015, respectively and was primarily comprised of available-for-sale investment purchases.

The net cash provided by financing activities was $259,000 for the six months ended June 30, 2016. This is primarily comprised of proceeds received from the recovery of related party short swing profits offset by stock issuance costs paid in the period for the prior year issuance of common stock. The net cash provided by financing activities was $254,000 for the six months ended June 30, 2015 and was primarily comprised of exercised options.

Our primary use of capital has been for the continued development and investment in commercialization readiness of the ACCELERATE PHENO™ system. We believe our capital requirements will continue to be met with our existing cash balance and those provided under grants, exercises of warrants and stock options and/or, additional issuance of equity or debt securities. However, if capital requirements vary materially from those currently planned, we may require additional capital sooner than expected. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders.

Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements as of June 30, 2016.


Item 3. Quantitative and Qualitative Disclosures

Interest Rate Risk

Our investment portfolio is exposed to market risk from changes in interest rates. The fair market value of fixed rate securities may be adversely impacted by fluctuations in interest rates while income earned on floating rate securities may decline as a result of decreases in interest rates. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would change the fair value of our interest sensitive financial instruments by approximately $495,000.
Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. Further information regarding our investments is included in Item 1, Note 5, Investments.


20



Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of June 30, 2016 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the period ended June 30, 2016 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On March 19, 2015, a putative securities class action lawsuit was filed against Accelerate Diagnostics, Inc., Lawrence Mehren, and Steve Reichling, Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504. The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System. Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015. On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class. On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud. Plaintiff sought certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order. Defendants moved to dismiss the amended complaint on July 21, 2015. The Court granted the motion and dismissed the case with prejudice on January 28, 2016. On February 26, 2016, Plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit, which challenges the dismissal of the amended complaint. Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016). The appeal is pending; Plaintiff filed her Brief on Appeal on June 6, 2016.

Item 1A. Risk Factors

There have been no material changes to the risk factors that were disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.


Item 3. Defaults Upon Senior Securities

Not applicable.


21



Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.


Item 6. Exhibits

Exhibit No.
Description
Filing Information
10.1
Registrant’s 2016 Employee Stock Purchase Plan*
Incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement filed with the SEC on April 1, 2016
31.1
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
31.2
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Filed herewith
32
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Filed herewith
101**
XBRL Instance Document
 
101**
XBRL Taxonomy Extension Schema Document
 
101**
XBRL Taxonomy Calculation Linkbase Document
 
101**
XBRL Taxonomy Extension Definition Linkbase Document
 
101**
XBRL Taxonomy Label Linkbase Document
 
101**
XBRL Taxonomy Presentation Linkbase Document
 

*Management compensatory plan or arrangement.

** Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 406T, these interactive data files are deemed not filed and otherwise are not subject to liability.


22


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACCELERATE DIAGNOSTICS, INC.
August 8, 2016
/s/ Lawrence Mehren
 
Lawrence Mehren
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
August 8, 2016
/s/ Steve Reichling
 
Steve Reichling
Chief Financial Officer
 
(Principal Financial and Accounting Officer)


23
 EX-31.1 2 accelerate-06302016xexh311.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lawrence Mehren, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchanged Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
designed such internal control over financial reporting, caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
August 8, 2016
/s/ Lawrence Mehren
 
Lawrence Mehren
President and Chief Executive Officer
 
(Principal Executive Officer)


 EX-31.2 3 accelerate-06302016xexh312.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13A-14 OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steve Reichling, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchanged Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
designed such internal control over financial reporting, caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
August 8, 2016
/s/ Steve Reichling
 
Steve Reichling
Chief Financial Officer
 
(Principal Financial and Accounting Officer)


 EX-32 4 accelerate-06302016xexh32.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of Accelerate Diagnostics, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2016 to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 8, 2016
/s/ Lawrence Mehren
 
Lawrence Mehren
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
August 8, 2016
/s/ Steve Reichling
 
Steve Reichling
Chief Financial Officer
 
(Principal Financial and Accounting Officer)


 EX-101.INS 5 axdx-20160630.xml XBRL INSTANCE DOCUMENT 0000727207 2016-01-01 2016-06-30 0000727207 2016-08-04 0000727207 2016-06-30 0000727207 2015-12-31 0000727207 2015-04-01 2015-06-30 0000727207 2016-04-01 2016-06-30 0000727207 2015-01-01 2015-06-30 0000727207 2015-06-30 0000727207 2014-12-31 0000727207 us-gaap:FairValueInputsLevel1Member 2015-12-31 0000727207 us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:InvestmentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:InvestmentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel2Member 2015-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000727207 us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000727207 us-gaap:InvestmentsMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:InvestmentsMember 2015-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:AssetBackedSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:InvestmentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:AssetBackedSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:InvestmentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2016-06-30 0000727207 us-gaap:InvestmentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:AssetBackedSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CertificatesOfDepositMember 2016-06-30 0000727207 us-gaap:USTreasuryAndGovernmentMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:InvestmentsMember 2016-06-30 0000727207 us-gaap:CertificatesOfDepositMember 2016-06-30 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2016-06-30 0000727207 us-gaap:CashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:CorporateDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2016-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-06-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2016-01-01 2016-06-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2016-01-01 2016-06-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2015-01-01 2015-06-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2015-01-01 2015-12-31 0000727207 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2015-01-01 2015-12-31 0000727207 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2016-06-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember axdx:DenverHealthMember 2015-12-31 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-06-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-06-30 0000727207 us-gaap:ConstructionInProgressMember 2015-12-31 0000727207 us-gaap:ConstructionInProgressMember 2016-06-30 0000727207 us-gaap:TechnologyEquipmentMember 2015-12-31 0000727207 us-gaap:TechnologyEquipmentMember 2016-06-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2015-12-31 0000727207 us-gaap:ComputerEquipmentMember 2016-06-30 0000727207 us-gaap:ComputerEquipmentMember 2015-12-31 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-02-01 2015-02-28 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2012-05-01 2016-06-30 0000727207 us-gaap:MinimumMember 2012-08-01 2012-08-31 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2012-05-01 2012-05-31 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-01-01 2015-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-02-15 2016-01-31 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2015-04-01 2015-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2016-01-01 2016-06-30 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2015-01-01 2015-06-30 0000727207 2012-08-01 2012-08-31 0000727207 axdx:NationalInstituteofHealthGrantMember 2016-04-01 2016-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-04-01 2015-06-30 0000727207 2012-08-31 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2016-01-01 2016-06-30 0000727207 axdx:DefenseMedicalResearchandDevelopmentProgramMember 2016-04-01 2016-06-30 0000727207 2015-01-01 2015-12-31 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-04-01 2015-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-04-01 2016-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-06-30 0000727207 axdx:OptionsOutstandingMember 2016-01-01 2016-06-30 0000727207 axdx:OptionsExercisableMember 2016-06-30 0000727207 axdx:OptionsVestedAndExpectedToVestMember 2016-06-30 0000727207 axdx:OptionsOutstandingMember 2016-06-30 0000727207 axdx:OptionsExercisableMember 2016-01-01 2016-06-30 0000727207 axdx:OptionsVestedAndExpectedToVestMember 2016-01-01 2016-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2016-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0000727207 axdx:RecoveryofShortSwingProfitsMember 2016-06-01 2016-06-30 xbrli:pure axdx:segment axdx:job iso4217:USD xbrli:shares axdx:milestone xbrli:shares iso4217:USD 114000 43000 0 991000 P35M P5Y 63000 4500000 65 15 40 30 4 0.65 false --12-31 Q2 2016 2016-06-30 10-Q 0000727207 51228452 Accelerated Filer Accelerate Diagnostics, Inc. 2543000 2642000 2623000 1789000 2622000 3769000 -12000 69000 243894000 248776000 2528000 747000 1781000 4185000 1435000 2750000 2235000 462000 1773000 3921000 664000 3257000 3000 5000 3000 5000 6778580 7529452 139324000 110515000 134151000 105403000 132424000 120585000 0 120585000 0 0 11839000 2507000 0 9332000 11839000 0 0 0 0 0 2507000 120585000 9332000 11839000 102438000 57971000 0 36121000 6028000 0 0 21850000 0 15822000 44467000 7095000 1398000 0 499000 31465000 43069000 4010000 0 0 0 0 0 0 0 0 0 0 7095000 37519000 6028000 499000 31465000 64919000 4010000 15822000 11851000 64849000 11839000 2507000 9332000 64919000 7095000 6028000 499000 31465000 4010000 15822000 1000 0 1000 81000 11000 0 0 27000 1000 42000 13000 3000 10000 11000 0 0 0 11000 0 0 11851000 2510000 9341000 64849000 7084000 6028000 499000 31449000 4009000 15780000 0 0 0 0 0 37332000 0 37384000 11851000 27517000 11839000 27535000 11839000 64919000 13000 0 53563000 35231000 120585000 37519000 -18332000 -83066000 0 0 0.001 0.001 55000000 75000000 51191184 51218417 51191184 51218417 51000 51000 -12260000 -21153000 -17788000 -32859000 0.00 0.66 1.00 0.76 0.70 1.00 12287000 21212000 17909000 33244000 1000000 1000000 1000000.0 1000000 1000000.0 127000 43000 127000 43000 13000 0 1000000 1000000 729000 1147000 403000 729000 605000 1147000 -0.27 -0.47 -0.35 -0.64 482000 12400000 17.55 9.66 157000 152000 0 0 -117000 -73000 4755000 7622000 9239000 16676000 -129000 -394000 65000 92000 657000 1175000 -14000 -84000 0 1220000 675000 -272000 18000 33000 140000 194000 -99000 -123000 11839000 64919000 167000 282000 280000 540000 6306000 5474000 139324000 110515000 5306000 4474000 1000000 1000000 19000 33000 20000 40000 0 0 0 0 254000 259000 -2229000 -55238000 -16357000 -28087000 -12252000 -21149000 -17866000 -32940000 1 -12268000 -21179000 -17889000 -33061000 675000 0 0 4000 173000 498000 12000 1232000 -8000 -4000 29000 81000 0 0 49000 0 16000 30000 23000 121000 -2000 -3000 0 0 0 814000 8017000 63534000 2160000 2084000 5000000 5000000 0 0 0 0 1638000 1564000 34000 141000 500000 1000000 7807000 9380000 327000 95000 7638000 1877000 2183000 1772000 1806000 8729000 2173000 736000 3491000 2329000 5016000 4960000 77000 50000 169000 129000 866000 73000 13000 2000000 5000000 689000 0 0 50000 59000 7126000 12856000 8062000 15416000 178000 358000 760000 1424000 602000 0 68000 647000 136000 0 44000 1200000 44000 -110915000 -143855000 0 0 0 143000 19000 33000 20000 183000 4185000 3921000 0 0.00 0 0.00 20.91 20.91 0 0.00 0 0 0.92 0.85 0.0173 0.0145 40250 40250 1789 119706 899600 6167170 6918042 6.91 7.49 3.49 13.49 20.06 13.09 4268778 6918042 6715032 P6Y4M24D P6Y2M12D 34813000 37775000 38171000 3.77 5.80 5.63 P6Y4M28D P7Y0M22D P7Y 5.01 7.49 7.28 27233 133018000 105041000 44678000 44664000 51213000 51205000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Defense Medical Research and Development Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (&#8220;DMRDP&#8221;) recommended </font><font style="font-family:Arial;font-size:10pt;">$2.0 million</font><font style="font-family:Arial;font-size:10pt;"> of funding for a proposed </font><font style="font-family:Arial;font-size:10pt;">35</font><font style="font-family:Arial;font-size:10pt;">-month project. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections. The project will apply the ACCELERATE PHENO&#8482; system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of </font><font style="font-family:Arial;font-size:10pt;">$602,000</font><font style="font-family:Arial;font-size:10pt;"> under this grant which is recorded as an offset to research and development expenses. The amounts invoiced for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$44,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$68,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$44,000</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$136,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. The period of performance of this grant was extended through September 2016.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;"> year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood. In June 2015, the Company executed a subaward agreement with Denver Health for the services provided as part of this grant which covered the period of February 15, 2015 through January 31, 2016 and totaled </font><font style="font-family:Arial;font-size:10pt;">$689,000</font><font style="font-family:Arial;font-size:10pt;">. The amounts invoiced for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$59,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, respectively. Amounts invoiced under this grant are recorded as an offset to research and development expenses. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the &#8220;Grant Agreement&#8221;) with the Arizona Commerce Authority, an agency of the State of Arizona (the &#8220;Authority&#8221;), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the &#8220;Project&#8221;). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> (the &#8220;Grant&#8221;) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 &#8211; Relocation of Company&#8217;s operations and corporate headquarters to Arizona and creation of </font><font style="font-family:Arial;font-size:10pt;">15</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 &#8211; Creation of </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 &#8211; Creation of </font><font style="font-family:Arial;font-size:10pt;">40</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 &#8211; Creation of </font><font style="font-family:Arial;font-size:10pt;">65</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a &#8220;Qualified Job&#8221; is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;"> and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;"> of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestones. The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are &#8220;claw-back&#8221; provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the &#8220;claw-back&#8221; provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 8, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&amp;D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a &#8220;Certificate of Qualification&#8221; from the Arizona Commerce Authority (&#8220;Authority&#8221;), which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&amp;D Refundable Tax Credit Program"). The amounts incurred under this program are recorded as an offset to research and development expenses, and for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> amounts were incurred for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">. The refund for the 2014 tax year has been received and the amount for the 2015 tax year remains outstanding and is recorded as other current assets on the Condensed Consolidated Balance Sheets. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the maturities of the Company&#8217;s available-for-sale securities at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 1-5 years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 6-10 years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, (&#8220;U.S. GAAP&#8221;), and applicable rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;), regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, as filed with the SEC on March 9, 2016. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;"> or any future period.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accelerate Diagnostics, Inc. (&#8220;we&#8221; or &#8220;us&#8221; or &#8220;our&#8221; or &#8220;Accelerate&#8221; or &#8220;the Company&#8221;) is an </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:Arial;font-size:10pt;"> diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, (&#8220;U.S. GAAP&#8221;), and applicable rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;), regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, as filed with the SEC on March 9, 2016. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Arial;font-size:10pt;"> or any future period.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. During the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> new entities were formed based in Europe.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Investments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities, certificates of deposit, and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&#8217;s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the de novo request being granted by the U.S.&#160;FDA. Accordingly, the Company does not capitalize pre-launch inventory prior to receipt of marketing&#160;authorization, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted. Costs associated with the Company&#8217;s purchase of inventory are either reported as research and development costs, or if the inventory is used in marketing evaluations, as sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue in accordance with ASC 605, &#8220;Revenue Recognition,&#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue represents amounts received but not yet earned under existing agreements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from operations includes product sales, principally of ACCELERATE PHENO&#8482; systems (formerly referred to as Accelerate ID/AST systems). When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Warranty </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A limited warranty of less than a year is covered under selected contracts. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in sales, general and administrative on the condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows ASC 830 "Foreign Currency Matters," which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are included in the foreign currency translation adjustment, within the condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain or loss, within the condensed consolidated statements of operations and comprehensive loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. COMMITMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona and Europe, the last of which expires in 2018. Total rent expense, including common area charges was </font><font style="font-family:Arial;font-size:10pt;">$280,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$167,000</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$540,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$282,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. Future minimum lease payments under operating lease agreements are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Agreements</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. The Company incurred clinical trial expense of </font><font style="font-family:Arial;font-size:10pt;">$760,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$178,000</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">, respectively, and </font><font style="font-family:Arial;font-size:10pt;">$1,424,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$358,000</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">, respectively. The expense incurred as part of the clinical trial is included in research and development on the condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On March 19, 2015, a putative securities class action lawsuit was filed against Accelerate Diagnostics, Inc., Lawrence Mehren, and Steve Reichling, Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504. The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System. Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015. On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class. On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud. Plaintiff sought certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order. Defendants moved to dismiss the amended complaint on July 21, 2015. The Court granted the motion and dismissed the case with prejudice on January 28, 2016. On February 26, 2016, Plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit, which challenges the dismissal of the amended complaint. Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016). The appeal is pending; Plaintiff filed her Brief on Appeal on June 6, 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. CONCENTRATION OF CREDIT RISK</font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">70%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> of the Company&#8217;s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company extends credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$129,000</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">76%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$50,000</font><font style="font-family:Arial;font-size:10pt;"> or </font><font style="font-family:Arial;font-size:10pt;">66%</font><font style="font-family:Arial;font-size:10pt;">, respectively, of the Company&#8217;s outstanding receivable balance was with Denver Health Medical Center (&#8220;Denver Health&#8221;). See </font><font style="font-family:Arial;font-size:10pt;">Note 7, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;"> for more information.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from product sales purchased from Denver Health represented </font><font style="font-family:Arial;font-size:10pt;">100%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">0%</font><font style="font-family:Arial;font-size:10pt;"> for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> respectively. There were no product sales for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. During the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> new entities were formed based in Europe.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30,</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Products not yet delivered</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes option activity under all plans during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month period ending </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options outstanding January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">899,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(119,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(27,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,918,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">7.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Black-Scholes Assumptions for Options Granted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">92%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.45%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$9.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$17.55</font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Supplemental Information</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Exercisable</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Vested and Expected to Vest</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,918,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,268,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,715,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average remaining contractual term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aggregate intrinsic value (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">37,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">34,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes restricted stock unit activity during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month period ending </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted Stock Unit (RSU) Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs Outstanding January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested/released</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs outstanding June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expense recognized on Company&#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Equity-Based Compensation Expenses</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">664</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,435</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,528</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,921</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock units was </font><font style="font-family:Arial;font-size:10pt;">$12.4 million</font><font style="font-family:Arial;font-size:10pt;"> and $</font><font style="font-family:Arial;font-size:10pt;">482,000</font><font style="font-family:Arial;font-size:10pt;"> respectively. This is expected to be recognized over the years </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;"> through </font><font style="font-family:Arial;font-size:10pt;">2021</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The expense recognized on Company&#8217;s Statements of Operations and Comprehensive Loss related to options is summarized below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Equity-Based Compensation Expenses</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6/30/2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">664</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,435</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Sales, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Equity-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,528</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3,921</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. EARNINGS PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The financial statements show basic and diluted loss per share.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company&#8217;s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our common stock to be antidilutive. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">, and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">, there were common stock options, restricted stock units and warrants exercisable for </font><font style="font-family:Arial;font-size:10pt;">7,529,452</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">6,778,580</font><font style="font-family:Arial;font-size:10pt;"> shares of common stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices<br clear="none"/>in Active<br clear="none"/>Markets for<br clear="none"/>Identical<br clear="none"/>Assets<br clear="none"/>(Level 1)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial Paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21,850</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43,069</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">57,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">102,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices<br clear="none"/>in Active<br clear="none"/>Markets for<br clear="none"/>Identical<br clear="none"/>Assets<br clear="none"/>(Level 1) &#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">132,424</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. FAIR VALUE OF FINANCIAL INSTRUMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices<br clear="none"/>in Active<br clear="none"/>Markets for<br clear="none"/>Identical<br clear="none"/>Assets<br clear="none"/>(Level 1)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Unobservable<br clear="none"/>Inputs<br clear="none"/>(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">36,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,519</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial Paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">21,850</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43,069</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">57,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">44,467</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">102,438</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Quoted Prices<br clear="none"/>in Active<br clear="none"/>Markets for<br clear="none"/>Identical<br clear="none"/>Assets<br clear="none"/>(Level 1) &#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs<br clear="none"/>(Level 3)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investments:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total assets measured at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">120,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">132,424</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts, money market funds, certificates of deposit and U.S. Treasury securities as these specific assets are liquid.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no transfers between levels during the six month period ended </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company follows ASC 830 "Foreign Currency Matters," which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are included in the foreign currency translation adjustment, within the condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain or loss, within the condensed consolidated statements of operations and comprehensive loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the de novo request being granted by the U.S.&#160;FDA. Accordingly, the Company does not capitalize pre-launch inventory prior to receipt of marketing&#160;authorization, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted. Costs associated with the Company&#8217;s purchase of inventory are either reported as research and development costs, or if the inventory is used in marketing evaluations, as sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Investments</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities, certificates of deposit, and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment&#8217;s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. INVESTMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the Company&#8217;s available-for-sale investments at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 30, 2016</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes the maturities of the Company&#8217;s available-for-sale securities at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENT MATURITIES</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 1-5 years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">37,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Due in 6-10 years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Proceeds from sales of marketable securities (including principal paydowns), for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$500,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$34,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> were </font><font style="font-family:Arial;font-size:10pt;">$1,000,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$141,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> gross realized gains or losses from sales of marketable securities for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and there have been no other indicators of impairment. The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional information regarding the fair value of our financial instruments is included in </font><font style="font-family:Arial;font-size:10pt;">Note 3, Fair Value of Financial Instruments</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an "incurred loss" methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020 with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for us on January 1, 2017 with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements and plan to adopt on the effective date.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019 with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;"> Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation. We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers Deferral of the Effective Date, which deferred the effective date resulting in a new effective date of January 1, 2018 for us. We are permitted to adopt early but not before the original effective date of January 1, 2017. FASB has issued several other ASU's which provide further guidance on Topic 606 and have the same effective date. The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements. We are currently evaluating the transition method and the adoption date that will be elected. We will implement ASU 2014-09 and all relevant subsequently issued ASU's on Topic 606 concurrently.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an "incurred loss" methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020 with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for us on January 1, 2017 with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements and plan to adopt on the effective date.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019 with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Arial;font-size:10pt;"> Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation. We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers Deferral of the Effective Date, which deferred the effective date resulting in a new effective date of January 1, 2018 for us. We are permitted to adopt early but not before the original effective date of January 1, 2017. FASB has issued several other ASU's which provide further guidance on Topic 606 and have the same effective date. The standard allows for either &#8220;full retrospective&#8221; adoption, meaning the standard is applied to all of the periods presented, or &#8220;modified retrospective&#8221; adoption, meaning the standard is applied only to the most current period presented in the financial statements. We are currently evaluating the transition method and the adoption date that will be elected. We will implement ASU 2014-09 and all relevant subsequently issued ASU's on Topic 606 concurrently.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes restricted stock unit activity during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month period ending </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Restricted Stock Unit (RSU) Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs Outstanding January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Vested/released</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs outstanding June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">40,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">20.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Future minimum lease payments under operating lease agreements are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating Lease Obligations</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Year ending December 31:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost and consisted of the following at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30,</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technical equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Facilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital projects in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated depreciation - other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Depreciation expense (which includes amortization of capital lease assets) for the </font><font style="font-family:Arial;font-size:10pt;">three months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$605,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$403,000</font><font style="font-family:Arial;font-size:10pt;">, respectively, and for the </font><font style="font-family:Arial;font-size:10pt;">six months ended</font><font style="font-family:Arial;font-size:10pt;"> </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$1,147,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$729,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Property and equipment are recorded at cost and consisted of the following at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30,</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Technical equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,329</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Facilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3,491</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Capital projects in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Accumulated depreciation - other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3,769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net property and equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13. RELATED PARTY TRANSACTIONS</font><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In </font><font style="font-family:Arial;font-size:10pt;">June 2016</font><font style="font-family:Arial;font-size:10pt;">, the Company&#160;recorded a net amount of </font><font style="font-family:Arial;font-size:10pt;">$866,000</font><font style="font-family:Arial;font-size:10pt;"> related to the recovery of short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended.&#160;&#160;The Company recognized these related party proceeds as an increase to contributed capital on the condensed consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. DEFERRED REVENUE AND INCOME</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;"> follows:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Deferred Revenue and Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June 30,</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fisher agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Products not yet delivered</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total current deferred revenue and income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arizona Commerce Authority grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total long-term deferred income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have received </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in </font><font style="font-family:Arial;font-size:10pt;">Note 7, License Agreements and Grants</font><font style="font-family:Arial;font-size:10pt;">. As of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the &#8220;claw-back&#8221; provisions under the Grant Agreement expire in January 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company recognizes revenue in accordance with ASC 605, &#8220;Revenue Recognition,&#8221; when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred revenue represents amounts received but not yet earned under existing agreements.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Revenue from operations includes product sales, principally of ACCELERATE PHENO&#8482; systems (formerly referred to as Accelerate ID/AST systems). When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following tables summarize the Company&#8217;s available-for-sale investments at </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">June 30, 2016</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certificates of deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15,822</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">US Agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">31,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,849</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">64,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AVAILABLE-FOR-SALE INVESTMENTS</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gains</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Losses</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Corporate notes and bonds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9,332</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11,839</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table summarizes option activity under all plans during the </font><font style="font-family:Arial;font-size:10pt;">six</font><font style="font-family:Arial;font-size:10pt;">-month period ending </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Activity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of&#160;Shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options outstanding January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,167,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">899,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(119,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">20.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(27,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">13.49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Outstanding June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">6,918,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">7.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of </font><font style="font-family:Arial;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:Arial;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Stock Option Supplemental Information</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Exercisable</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Options Vested and Expected to Vest</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Number of options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,918,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">4,268,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6,715,032</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average remaining contractual term (in years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">7.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">3.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Aggregate intrinsic value (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">37,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">34,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">38,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Black-Scholes Assumptions for Options Granted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">6.4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">92%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Expected dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Risk free interest rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.45%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1.73%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Weighted average fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$9.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$17.55</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. SEGMENTS</font></div><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company operates as </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company&#8217;s business operates in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> operating segment because the Company&#8217;s chief operating decision maker evaluates the Company&#8217;s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in </font><font style="font-family:Arial;font-size:10pt;">one</font><font style="font-family:Arial;font-size:10pt;"> operating segment, all required financial segment information can be found in the consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Warranty </font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A limited warranty of less than a year is covered under selected contracts. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in sales, general and administrative on the condensed consolidated statements of operations and comprehensive loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 14. SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As Defendants in the securities litigation now pending before the United States Court of Appeals for the Ninth Circuit (Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016)), we filed our answering brief with the Court on August 3, 2016. Should Plaintiff choose to file an optional reply brief, that&#160;brief&#160;will be due on August 22, 2016, unless Plaintiff requests - and the Court grants - an extension of time.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional information regarding this litigation is included in </font><font style="font-family:Arial;font-size:10pt;">Note 11, Commitments</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div> EX-101.SCH 6 axdx-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2112100 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Commitments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Commitments - Operating Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATEDSTATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Deferred Revenue and Income link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Deferred Revenue and Income (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Deferred Revenue and Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Employee and Consultant Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Employee and Consultant Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Investments - Schedule of Available-For-Sale Investment Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - License Agreements and Grants link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details) link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - License Agreements and Grants - Defense Medical Research and Development Program (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - License Agreements and Grants - National Institute of Health Grant (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Segments (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axdx-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 axdx-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 axdx-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Risks and Uncertainties [Abstract] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash and cash equivalents Cash and Cash Equivalents [Member] Accounts receivable Accounts Receivable [Member] Revenue from product sales Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Concentration of Credit Risk Credit Concentration Risk [Member] Customer Concentration Risk Customer Concentration Risk [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Denver Health Denver Health [Member] Denver Health [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Risk concentration (percent) Concentration Risk, Percentage Trade accounts receivable Receivables, Net, Current License Agreements and Grants - Research and Development [Abstract] License Agreements and Grants - Research and Development [Abstract] License Agreements and Grants License Agreements and Grants License agreements New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recently Issued Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Accounting Policies [Abstract] Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Business Description and Basis of Presentation [Text Block] Document And Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Earnings Per Share [Abstract] Earnings Per Share Earnings Per Share [Text Block] Antidilutive common stock instruments outstanding (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Segment Reporting [Abstract] Segments Segment Reporting Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Certificates of deposit Certificates of Deposit [Member] US Treasury securities US Treasury and Government [Member] US Agency securities US Government Agencies Debt Securities [Member] Commercial Paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Asset-backed securities Asset-backed Securities [Member] Corporate notes and bonds Corporate Debt Securities [Member] Total investments Investments [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets measured at fair value Assets, Fair Value Disclosure, Recurring Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Number of operating segments Number of Operating Segments Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Option Indexed to Issuer's Equity [Table] Option Indexed to Issuer's Equity [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed To Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Options Outstanding Options Outstanding Options Outstanding Options Exercisable Options Exercisable Options Exercisable Options Vested and Expected to Vest Options Vested and Expected To Vest Options Vested and Expected To Vest Option Indexed to Issuer's Equity [Line Items] Option Indexed to Issuer's Equity [Line Items] Number of options (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average exercise price (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Weighted average fair value (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate intrinsic value (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Investments, Debt and Equity Securities [Abstract] Amortized Cost Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract] Due in less than 1 year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Due in 1-5 years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Due in 6-10 years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis Total Available-for-sale Debt Securities, Amortized Cost Basis Fair Value Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Due in less than 1 year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Due in 1-5 years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Due in 6-10 years Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value Total Available-for-sale Securities, Debt Securities Income Statement [Abstract] Revenues: Revenues, Net of Interest Expense [Abstract] Product sales Sales Revenue, Goods, Gross Licensing and royalty revenues Licenses Revenue Total revenues Revenue, Net Costs and expenses: Costs and Expenses [Abstract] Research and development Research and Development Expense Sales, general and administrative General and Administrative Expense Amortization Amortization of Intangible Assets Depreciation Depreciation, Depletion and Amortization Total costs and expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest expense and other Other Nonoperating Income (Expense) Foreign currency exchange loss Foreign Currency Transaction Gain (Loss), before Tax Interest and dividend income Investment Income, Interest and Dividend Total other income Other Nonoperating Income Net loss Net Income (Loss) Attributable to Parent Basic and diluted net loss per share (dollars per share) Earnings Per Share, Basic and Diluted Weighted average shares outstanding (shares) Weighted Average Number of Shares Outstanding, Basic Other comprehensive loss: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Net loss Net unrealized gain (loss) on available-for-sale investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Employee and Consultant Equity-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Deferred Revenue Disclosure [Abstract] Fisher agreement Deferred Revenue, Current Products not yet delivered Deferred Revenue, Research Use Only Deferred Revenue, Research Use Only Total current deferred revenue and income Deferred Revenue and Credits Arizona Commerce Authority grant Deferred Credits and Other Liabilities Total long-term deferred income Deferred Revenue, Noncurrent Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Computer equipment Computer Equipment [Member] Technical equipment Technology Equipment [Member] Facilities Leaseholds and Leasehold Improvements [Member] Capital projects in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Gross Accumulated depreciation - other Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net property and equipment Property, Plant and Equipment, Net Commitments and Contingencies Disclosure [Abstract] Commitments Commitments and Contingencies Disclosure [Text Block] Proceeds from sales of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Gross realized gains or losses from sales of marketable securities Marketable Securities, Realized Gain (Loss) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] Sales, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Equity-based compensation expense Allocated Share-based Compensation Expense Unrecognized equity-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized equity-based compensation cost, restricted stock units Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Statement of Financial Position [Abstract] Common Stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common Stock, shares authorized (shares) Common Stock, Shares Authorized Common Stock, shares issued (shares) Common Stock, Shares, Issued Common Stock, shares outstanding (shares) Common Stock, Shares, Outstanding Preferred Stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred Stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Operating Leases Obligations Operating Leases of Lessee Disclosure [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Outstanding, beginning balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Vested/Released (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Outstanding, ending balance (shares) Weighted Average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restricted Stock Outstanding, beginning balance (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Forfeited (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Vested/Released (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Restricted Stock Outstanding, ending balance (dollars per share) Fair Value Measurement Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Rent expense Operating Leases, Rent Expense Product Liability Contingency [Table] Product Liability Contingency [Table] Product Liability Contingency [Line Items] Product Liability Contingency [Line Items] Clinical trial expense Research and Development Expense (Excluding Acquired in Process Cost) Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Recovery of short-swing profit Recovery of Short-Swing Profits [Member] Recovery of Short-Swing Profits [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Recovery of related party short-swing profits Related Party Transaction, Amounts of Transaction Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Project [Axis] Project [Axis] Project [Domain] Project [Domain] National Institute of Health Grant National Institute of Health Grant [Member] National Institute of Health Grant [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Length of project (years) Research and Development Arrangement, Contract to Perform for Others, Proposed Period Research and Development Arrangement, Contract to Perform for Others, Proposed Period Total grant funding Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Schedule of Available-for-Sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of Available-For-Sale Investment Maturities Available-for-sale Securities [Table Text Block] Defense medical research and development program Defense Medical Research and Development Program [Member] Defense Medical Research and Development Program [Member] Length of project (months) Offset to research and development project Research and Development in Process Property and Equipment Property, Plant and Equipment [Table Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investments Investments Prepaid expenses Prepaid Expense and Other Assets, Current Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Intellectual property, net Finite-Lived Intangible Assets, Net Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accounts Payable and Accrued Liabilities, Current Deferred revenue and income Deferred Revenue Capital lease obligations Capital Lease Obligations Total current liabilities Liabilities, Current Long-term deferred income Liabilities, Other than Long-term Debt, Noncurrent Total liabilities Liabilities Commitments and contingencies see Note 11, Commitments Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value; 75,000,000 common shares authorized with 51,218,417 shares issued and outstanding on June 30, 2016 and 55,000,000 authorized with 51,191,184 shares issued and outstanding on December 31, 2015 Common Stock, Value, Outstanding 5,000,000 preferred shares authorized and none outstanding as of June 30, 2016 and December 31, 2015 Preferred Stock, Value, Issued Contributed capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive gain (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Volatility (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments Risk free interest rates (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Fair value per share (dollars per share) Fair Value Inputs, Price Earnings Ratio Multiple Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of intangible assets Amortization of investment discount Investment Income, Net, Amortization of Discount and Premium Equity-based compensation Share-based Compensation (Increase) decrease in assets: Increase (Decrease) in Operating Assets [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expense and other Increase (Decrease) in Prepaid Expense and Other Assets Other current assets Increase (Decrease) in Other Current Assets Increase (decrease) in liabilities: Increase (Decrease) in Accrued Liabilities [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Deferred revenue and income Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Productive Assets Purchases of available-for-sale securities Payments to Acquire Marketable Securities Sales of available-for-sale securities Maturity of available-for-sale securities Proceeds from Sale and Maturity of Marketable Securities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Exercise of options Proceeds from Stock Options Exercised Common stock issuance costs Payments of Stock Issuance Costs Payments on capital lease obligations Repayments of Debt and Capital Lease Obligations Recovery of related party short-swing profits Proceeds From Recovery of Related Party Short-Swing Profits Proceeds From Recovery of Related Party Short-Swing Profits Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Deferred Revenue and Income Revenue Recognition, Deferred Revenue [Policy Text Block] Deferred Revenue and Income Summary Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Year ending December 31: Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2016 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2017 Operating Leases, Future Minimum Payments, Due in Two Years 2018 Operating Leases, Future Minimum Payments, Due in Three Years 2019 Operating Leases, Future Minimum Payments, Due in Four Years Thereafter Operating Leases, Future Minimum Payments, Due in Five Years Total operating lease obligations Operating Leases, Future Minimum Payments Due Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Number of milestones Revenue Recognition, Milestone Method, Number Of Milestones Revenue Recognition, Milestone Method, Number Of Milestones Qualified jobs created, milestone one Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone One Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone One Qualified jobs created, milestone two Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Two Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Two Qualified jobs created, milestone three Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Three Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Three Qualified jobs created, milestone four Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Four Revenue Recognition, Milestone Method, Milestone, Jobs Created, Milestone Four Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Capital investment milestone Revenue Recognition, Milestone Method, Milestone, Capital Investment Revenue Recognition, Milestone Method, Milestone, Capital Investment Grant related minimum annual wages Revenue Recognition, Milestone Method, Annual Wages Revenue Recognition, Milestone Method, Annual Wages Percent of company paid premiums Revenue Recognition, Milestone Method, Percent of Company Paid Premiums Revenue Recognition, Milestone Method, Percent of Company Paid Premiums Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Investments Investment, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Revenue Revenue Recognition, Policy [Policy Text Block] Warranty Standard Product Warranty, Policy [Policy Text Block] Foreign Currency Translation and Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Investment [Table] Investment [Table] Investment [Line Items] Investment [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair Value Available-for-sale Securities Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Black-Scholes Assumptions for Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock Option Supplemental Information Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] Restricted Stock Unit (RSU) Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Equity-Based Compensation Expenses Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, ending balance (shares) Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Outstanding, beginning balance (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Exercised (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Expired (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, ending balance (dollars per share) EX-101.PRE 10 axdx-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2016
Aug. 04, 2016
Document And Entity Information    
Entity Registrant Name Accelerate Diagnostics, Inc.  
Entity Central Index Key 0000727207  
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   51,228,452
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2016  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 37,519 $ 120,585
Investments 64,919 11,839
Trade accounts receivable 169 77
Prepaid expenses 1,564 1,638
Other current assets 1,232 12
Total current assets 105,403 134,151
Property and equipment, net 4,960 5,016
Intellectual property, net 152 157
Total assets 110,515 139,324
Current liabilities:    
Accounts payable 1,789 2,623
Accrued liabilities 2,642 2,543
Deferred revenue and income 43 127
Capital lease obligations 0 13
Total current liabilities 4,474 5,306
Long-term deferred income 1,000 1,000
Total liabilities 5,474 6,306
Commitments and contingencies see Note 11, Commitments 0 0
Stockholders' equity:    
Common stock, $0.001 par value; 75,000,000 common shares authorized with 51,218,417 shares issued and outstanding on June 30, 2016 and 55,000,000 authorized with 51,191,184 shares issued and outstanding on December 31, 2015 51 51
5,000,000 preferred shares authorized and none outstanding as of June 30, 2016 and December 31, 2015 0 0
Contributed capital 248,776 243,894
Accumulated deficit (143,855) (110,915)
Accumulated other comprehensive gain (loss) 69 (12)
Total stockholders' equity 105,041 133,018
Total liabilities and stockholders' equity $ 110,515 $ 139,324
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Common Stock, par value (usd per share) $ 0.001 $ 0.001
Common Stock, shares authorized (shares) 75,000,000 55,000,000
Common Stock, shares issued (shares) 51,218,417 51,191,184
Common Stock, shares outstanding (shares) 51,218,417 51,191,184
Preferred Stock, shares authorized (shares) 5,000,000 5,000,000
Preferred Stock, shares outstanding (shares) 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenues:        
Product sales $ 0 $ 0 $ 143 $ 0
Licensing and royalty revenues 20 19 40 33
Total revenues 20 19 183 33
Costs and expenses:        
Research and development 8,062 7,126 15,416 12,856
Sales, general and administrative 9,239 4,755 16,676 7,622
Amortization 3 3 5 5
Depreciation 605 403 1,147 729
Total costs and expenses 17,909 12,287 33,244 21,212
Loss from operations (17,889) (12,268) (33,061) (21,179)
Interest expense and other 0 (2) 0 (3)
Foreign currency exchange loss (117) 0 (73) 0
Interest and dividend income 140 18 194 33
Total other income 23 16 121 30
Net loss $ (17,866) $ (12,252) $ (32,940) $ (21,149)
Basic and diluted net loss per share (dollars per share) $ (0.35) $ (0.27) $ (0.64) $ (0.47)
Weighted average shares outstanding (shares) 51,213 44,678 51,205 44,664
Other comprehensive loss:        
Net loss $ (17,866) $ (12,252) $ (32,940) $ (21,149)
Net unrealized gain (loss) on available-for-sale investments 29 (8) 81 (4)
Foreign currency translation adjustment 49 0 0 0
Comprehensive loss $ (17,788) $ (12,260) $ (32,859) $ (21,153)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATEDSTATEMENT OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities:    
Net loss $ (32,940) $ (21,149)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,147 729
Amortization of intangible assets 5 5
Amortization of investment discount 123 99
Equity-based compensation 3,921 4,185
(Increase) decrease in assets:    
Accounts receivable (92) (65)
Prepaid expense and other 272 (675)
Other current assets (1,220) 0
Increase (decrease) in liabilities:    
Accounts payable (394) (129)
Accrued liabilities 1,175 657
Deferred revenue and income (84) (14)
Net cash used in operating activities (28,087) (16,357)
Cash flows from investing activities:    
Purchases of equipment (2,084) (2,160)
Purchases of available-for-sale securities (63,534) (8,017)
Sales of available-for-sale securities 1,000 141
Maturity of available-for-sale securities 9,380 7,807
Net cash used in investing activities (55,238) (2,229)
Cash flows from financing activities:    
Exercise of options 95 327
Common stock issuance costs (814) 0
Payments on capital lease obligations (13) (73)
Recovery of related party short-swing profits 991 0
Net cash provided by financing activities 259 254
Decrease in cash and cash equivalents (83,066) (18,332)
Cash and cash equivalents, beginning of period 120,585 53,563
Cash and cash equivalents, end of period $ 37,519 $ 35,231
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or “the Company”) is an in vitro diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC on March 9, 2016.

The condensed consolidated balance sheet as of December 31, 2015 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2016 or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. During the three months ended June 30, 2016 new entities were formed based in Europe.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities, certificates of deposit, and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.

Reclassification

Certain prior year amounts have been reclassified for consistency with the current year presentation.

Inventory

The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (“FDA”) or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the de novo request being granted by the U.S. FDA. Accordingly, the Company does not capitalize pre-launch inventory prior to receipt of marketing authorization, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted. Costs associated with the Company’s purchase of inventory are either reported as research and development costs, or if the inventory is used in marketing evaluations, as sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.

Revenue

The Company recognizes revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.

Deferred revenue represents amounts received but not yet earned under existing agreements.

Revenue from operations includes product sales, principally of ACCELERATE PHENO™ systems (formerly referred to as Accelerate ID/AST systems). When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return.

Warranty

A limited warranty of less than a year is covered under selected contracts. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in sales, general and administrative on the condensed consolidated statements of operations and comprehensive loss.

Foreign Currency Translation and Foreign Currency Transactions

The Company follows ASC 830 "Foreign Currency Matters," which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are included in the foreign currency translation adjustment, within the condensed consolidated statements of operations and comprehensive loss.

The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain or loss, within the condensed consolidated statements of operations and comprehensive loss.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Recently Issued Accounting Pronouncements
 6 Months Ended
Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Recently Issued Accounting Pronouncements
NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an "incurred loss" methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020 with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for us on January 1, 2017 with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements and plan to adopt on the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019 with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation. We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers Deferral of the Effective Date, which deferred the effective date resulting in a new effective date of January 1, 2018 for us. We are permitted to adopt early but not before the original effective date of January 1, 2017. FASB has issued several other ASU's which provide further guidance on Topic 606 and have the same effective date. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. We are currently evaluating the transition method and the adoption date that will be elected. We will implement ASU 2014-09 and all relevant subsequently issued ASU's on Topic 606 concurrently.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
NOTE 3. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at June 30, 2016 and December 31, 2015.

 
June 30, 2016
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
36,121

$
1,398

$
—

$
37,519

Investments:
 
 
 
 
Certificates of deposit
6,028

—

—

6,028

US Treasury securities
15,822

—

—

15,822

US Agency securities
—

4,010

—

4,010

Commercial Paper
—

499

—

499

Asset-backed securities
—

7,095

—

7,095

Corporate notes and bonds
—

31,465

—

31,465

Total investments
21,850

43,069

—

64,919

Total assets measured at fair value
$
57,971

$
44,467

$
—

$
102,438


 
December 31, 2015
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)  
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
120,585

$
—

$
—

$
120,585

Investments:
 
 
 
 
Asset-backed securities
—

2,507

—

2,507

Corporate notes and bonds
—

9,332

—

9,332

Total investments
—

11,839

—

11,839

Total assets measured at fair value
$
120,585

$
11,839

$
—

$
132,424



Level 1 assets are priced using quoted prices in active markets for identical assets which include cash accounts, money market funds, certificates of deposit and U.S. Treasury securities as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no transfers between levels during the six month period ended June 30, 2016.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Credit Risk
 6 Months Ended
Jun. 30, 2016
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk
NOTE 4. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, investments and accounts receivable, including receivables from major customers.

The Company’s main financial institution for banking operations held 70% and 100% of the Company’s cash and cash equivalents as of June 30, 2016 and December 31, 2015, respectively.

The Company extends credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At June 30, 2016 and December 31, 2015, $129,000 or 76% and $50,000 or 66%, respectively, of the Company’s outstanding receivable balance was with Denver Health Medical Center (“Denver Health”). See Note 7, License Agreements and Grants for more information.

Revenue from product sales purchased from Denver Health represented 100% and 0% for the six months ended June 30, 2016 and 2015 respectively. There were no product sales for the three months ended June 30, 2016 and 2015.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Investments
 6 Months Ended
Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]  
Investments
NOTE 5. INVESTMENTS

The following tables summarize the Company’s available-for-sale investments at June 30, 2016 and December 31, 2015:

AVAILABLE-FOR-SALE INVESTMENTS
June 30, 2016
(in thousands)
 
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit
$
6,028

$
—

$
—

$
6,028

US Treasury securities
15,780

42

—

15,822

US Agency securities
4,009

1

—

4,010

Commercial paper
499

—

—

499

Asset-backed securities
7,084

11

—

7,095

Corporate notes and bonds
31,449

27

(11
)
31,465

Total
$
64,849

$
81

$
(11
)
$
64,919


AVAILABLE-FOR-SALE INVESTMENTS
December 31, 2015
(in thousands)
 
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Asset-backed securities
$
2,510

$
—

$
(3
)
$
2,507

Corporate notes and bonds
9,341

1

(10
)
9,332

Total
$
11,851

$
1

$
(13
)
$
11,839



The following table summarizes the maturities of the Company’s available-for-sale securities at June 30, 2016 and December 31, 2015:

AVAILABLE-FOR-SALE INVESTMENT MATURITIES
(in thousands)
 
June 30, 2016
December 31, 2015
 
Amortized
Cost
Fair Value
Amortized
Cost
Fair Value
Due in less than 1 year
$
27,517

$
27,535

$
11,851

$
11,839

Due in 1-5 years
37,332

37,384

—

—

Due in 6-10 years
—

—

—

—

Total
$
64,849

$
64,919

$
11,851

$
11,839



Proceeds from sales of marketable securities (including principal paydowns), for the three months ended June 30, 2016 and 2015 were $500,000 and $34,000, respectively, and for the for the six months ended June 30, 2016 and 2015 were $1,000,000 and $141,000, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no gross realized gains or losses from sales of marketable securities for the three months ended and six months ended June 30, 2016 and 2015.

No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of June 30, 2016 and there have been no other indicators of impairment. The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost.

Additional information regarding the fair value of our financial instruments is included in Note 3, Fair Value of Financial Instruments.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
NOTE 6. PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost and consisted of the following at June 30, 2016 and December 31, 2015.
 
PROPERTY AND EQUIPMENT
(in thousands)
 
June 30,
December 31,
 
2016
2015
Computer equipment
$
2,173

$
1,877

Technical equipment
2,329

1,806

Facilities
3,491

1,772

Capital projects in progress
736

2,183

Total property and equipment
$
8,729

$
7,638

Accumulated depreciation - other
(3,769
)
(2,622
)
Net property and equipment
$
4,960

$
5,016



Depreciation expense (which includes amortization of capital lease assets) for the three months ended June 30, 2016 and 2015 was $605,000 and $403,000, respectively, and for the six months ended June 30, 2016 and 2015 was $1,147,000 and $729,000, respectively.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
License Agreements and Grants
 6 Months Ended
Jun. 30, 2016
License Agreements and Grants - Research and Development [Abstract]  
License Agreements and Grants
NOTE 7. LICENSE AGREEMENTS AND GRANTS

Defense Medical Research and Development Program

In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (“DMRDP”) recommended $2.0 million of funding for a proposed 35-month project. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections. The project will apply the ACCELERATE PHENO™ system to wound infections and other serious infections secondary to trauma. The Company has invoiced a cumulative total of $602,000 under this grant which is recorded as an offset to research and development expenses. The amounts invoiced for the three months ended June 30, 2016 and 2015 were $44,000 and $68,000, respectively, and for the six months ended June 30, 2016 and 2015 was $44,000 were $136,000, respectively. The period of performance of this grant was extended through September 2016.

National Institute of Health Grant

In February 2015, the National Institute of Health awarded Denver Health and the Company a five year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test carbepenem-resistant Enterobacteriaceae directly from whole blood. In June 2015, the Company executed a subaward agreement with Denver Health for the services provided as part of this grant which covered the period of February 15, 2015 through January 31, 2016 and totaled $689,000. The amounts invoiced for the three months ended June 30, 2016 and 2015 were $50,000 and $0, respectively, and for the six months ended June 30, 2016 and 2015 were $59,000 and $0, respectively. Amounts invoiced under this grant are recorded as an offset to research and development expenses.

Arizona Commerce Authority

In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1.0 million (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:

•
Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).

•
Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).

•
Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).

•
Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4.5 million.

For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of June 30, 2016, the Company has collected all of the $1.0 million in milestones. The full amount is recorded in long-term deferred income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in Note 8, Deferred Revenue and Income.

Arizona R&D Refundable Tax Credit Program

The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”), which allows the Company to be eligible for a partial refund of research and development investments ("Arizona R&D Refundable Tax Credit Program"). The amounts incurred under this program are recorded as an offset to research and development expenses, and for the six months ended June 30, 2016 and 2015 were $1.2 million and $647,000, respectively, and no amounts were incurred for the three months ended June 30, 2016 and 2015. The refund for the 2014 tax year has been received and the amount for the 2015 tax year remains outstanding and is recorded as other current assets on the Condensed Consolidated Balance Sheets. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Deferred Revenue and Income
 6 Months Ended
Jun. 30, 2016
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue and Income
NOTE 8. DEFERRED REVENUE AND INCOME

Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of June 30, 2016 and December 31, 2015 follows:
Deferred Revenue and Income
(in thousands)

June 30,
December 31,

2016
2015
Fisher agreement
$
—

$
13

Products not yet delivered
43

114

Total current deferred revenue and income
$
43

$
127






Arizona Commerce Authority grant
$
1,000

$
1,000

Total long-term deferred income
$
1,000

$
1,000



We have received $1.0 million in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in Note 7, License Agreements and Grants. As of June 30, 2016, no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the “claw-back” provisions under the Grant Agreement expire in January 2018.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share
NOTE 9. EARNINGS PER SHARE

The financial statements show basic and diluted loss per share.

The Company’s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our common stock to be antidilutive. As of June 30, 2016, and December 31, 2015, there were common stock options, restricted stock units and warrants exercisable for 7,529,452 and 6,778,580 shares of common stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Employee and Consultant Equity-Based Compensation
NOTE 10. EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION

The following table summarizes option activity under all plans during the six-month period ending June 30, 2016:

Stock Option Activity
 
Number of Shares
Weighted Average Exercise Price per Share
Options outstanding January 1, 2016
6,167,170

6.91

Granted
899,600

13.09

Forfeited
(119,706
)
20.06

Exercised
(27,233
)
3.49

Expired
(1,789
)
13.49

Options Outstanding June 30, 2016
6,918,042

7.49



The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:

Black-Scholes Assumptions for Options Granted
 
Three Months Ended
 
June 30, 2016
June 30, 2015
Expected term (in years)
6.2
6.4
Volatility
85%
92%
Expected dividends
—
—
Risk free interest rates
1.45%
1.73%
Weighted average fair value
$9.66
$17.55


The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of June 30, 2016:

Stock Option Supplemental Information
 
Options
Outstanding
Options
Exercisable
Options Vested and Expected to Vest
Number of options
6,918,042

4,268,778

6,715,032

Weighted average remaining contractual term (in years)
7.06

6.41

7.00

Weighted average exercise price
$
7.49

$
5.01

$
7.28

Weighted average fair value
$
5.80

$
3.77

$
5.63

Aggregate intrinsic value (in thousands)
$
37,775

$
34,813

$
38,171



The following table summarizes restricted stock unit activity during the six-month period ending June 30, 2016:

Restricted Stock Unit (RSU) Activity
 
Number of Shares
Weighted Average Grant Date Fair Value per Share
RSUs Outstanding January 1, 2016
40,250

20.91

Granted
—

—

Forfeited
—

—

Vested/released
—

—

RSUs outstanding June 30, 2016
40,250

20.91



The expense recognized on Company’s Statements of Operations and Comprehensive Loss related to options is summarized below:

Equity-Based Compensation Expenses
(in thousands)
 
Three Months Ended
Six Months Ended
 
6/30/2016
6/30/2015
6/30/2016
6/30/2015
Research and development
$
462

$
747

$
664

$
1,435

Sales, general and administrative
1,773

1,781

3,257

2,750

Equity-based compensation expense
$
2,235

$
2,528

$
3,921

$
4,185



As of June 30, 2016, unrecognized equity-based compensation cost related to unvested stock options and unvested restricted stock units was $12.4 million and $482,000 respectively. This is expected to be recognized over the years 2016 through 2021.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments
NOTE 11. COMMITMENTS

Leases

The Company has entered into lease agreements, lease amendments, and lease extensions ("Lease Agreements") for office, laboratory and manufacturing space located in Tucson, Arizona and Europe, the last of which expires in 2018. Total rent expense, including common area charges was $280,000 and $167,000 for the three months ended June 30, 2016 and 2015, respectively, and for the six months ended June 30, 2016 and 2015 was $540,000 and $282,000, respectively. Future minimum lease payments under operating lease agreements are as follows:

Operating Lease Obligations
(in thousands)
Year ending December 31:
 
2016
$
498

2017
173

2018
4

2019
—

Thereafter
—

Total operating lease obligations
$
675



Clinical Trial Agreements

The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. The Company incurred clinical trial expense of $760,000 and $178,000 for the three months ended June 30, 2016 and 2015, respectively, and $1,424,000 and $358,000 for the six months ended June 30, 2016 and 2015, respectively. The expense incurred as part of the clinical trial is included in research and development on the condensed consolidated statements of operations and comprehensive loss.

Legal Matters

On March 19, 2015, a putative securities class action lawsuit was filed against Accelerate Diagnostics, Inc., Lawrence Mehren, and Steve Reichling, Rapp v. Accelerate Diagnostics, Inc., et al., U.S. District Court, District of Arizona, 2:2015-cv-00504. The complaint alleges that we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5, by making false or misleading statements about our ID/AST System, formerly called the BACcel System. Plaintiff purports to bring the action on behalf of a class of persons who purchased or otherwise acquired our stock between March 7, 2014 and February 17, 2015. On June 9, 2015, Julia Chang was appointed Lead Plaintiff of the purported class. On June 23, 2015, Plaintiff filed an amended complaint alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b- 5, by making false or misleading statements or omissions about our ID/AST System and by allegedly employing schemes to defraud. Plaintiff sought certification of the action as a class action, compensatory damages for the class in an unspecified amount, legal fees and costs, and such other relief as the court may order. Defendants moved to dismiss the amended complaint on July 21, 2015. The Court granted the motion and dismissed the case with prejudice on January 28, 2016. On February 26, 2016, Plaintiff filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit, which challenges the dismissal of the amended complaint. Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016). The appeal is pending; Plaintiff filed her Brief on Appeal on June 6, 2016.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segments
 6 Months Ended
Jun. 30, 2016
Segment Reporting [Abstract]  
Segments
NOTE 12. SEGMENTS

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in one operating segment because the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. Since the Company operates in one operating segment, all required financial segment information can be found in the consolidated financial statements.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2016
Related Party Transactions [Abstract]  
Related Party Transactions
NOTE 13. RELATED PARTY TRANSACTIONS

In June 2016, the Company recorded a net amount of $866,000 related to the recovery of short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended.  The Company recognized these related party proceeds as an increase to contributed capital on the condensed consolidated balance sheet.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
 6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
NOTE 14. SUBSEQUENT EVENTS

As Defendants in the securities litigation now pending before the United States Court of Appeals for the Ninth Circuit (Chang v. Accelerate Diagnostics, Inc., et al., No. 2:15-CV-00504-SPL (9th Cir. filed Feb. 26, 2016)), we filed our answering brief with the Court on August 3, 2016. Should Plaintiff choose to file an optional reply brief, that brief will be due on August 22, 2016, unless Plaintiff requests - and the Court grants - an extension of time.

Additional information regarding this litigation is included in Note 11, Commitments.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC on March 9, 2016.

The condensed consolidated balance sheet as of December 31, 2015 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2016 or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation
Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. During the three months ended June 30, 2016 new entities were formed based in Europe.
Cash and Cash Equivalents
Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments
Investments

The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities, certificates of deposit, and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income.
Reclassification
Reclassification

Certain prior year amounts have been reclassified for consistency with the current year presentation.
Inventory
Inventory

The Company currently purchases and produces inventory prior to U.S. Food and Drug Administration (“FDA”) or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the de novo request being granted by the U.S. FDA. Accordingly, the Company does not capitalize pre-launch inventory prior to receipt of marketing authorization, unless the regulatory review process has progressed to a point that objective and persuasive evidence of regulatory approval is sufficiently probable, and future economic benefit can be asserted. Costs associated with the Company’s purchase of inventory are either reported as research and development costs, or if the inventory is used in marketing evaluations, as sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.
Revenue
Revenue

The Company recognizes revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.

Deferred revenue represents amounts received but not yet earned under existing agreements.

Revenue from operations includes product sales, principally of ACCELERATE PHENO™ systems (formerly referred to as Accelerate ID/AST systems). When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return.
Warranty
Warranty

A limited warranty of less than a year is covered under selected contracts. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in sales, general and administrative on the condensed consolidated statements of operations and comprehensive loss.
Foreign Currency Translation and Foreign Currency Transactions
Foreign Currency Translation and Foreign Currency Transactions

The Company follows ASC 830 "Foreign Currency Matters," which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. dollars are included in the foreign currency translation adjustment, within the condensed consolidated statements of operations and comprehensive loss.

The Company has assets and liabilities, primarily receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain or loss, within the condensed consolidated statements of operations and comprehensive loss.
Recently Issued Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an "incurred loss" methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020 with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for us on January 1, 2017 with early adoption permitted. We are currently evaluating the impact of this guidance on our financial statements and plan to adopt on the effective date.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019 with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We are carefully evaluating our existing revenue recognition practices to determine whether any contracts in the scope of the guidance will be affected by the new requirements. The effects may include identifying performance obligations in existing arrangements, determining the transaction price and allocating the transaction price to each separate performance obligation. We will also establish practices to determine when a performance obligation has been satisfied, and recognize revenue in accordance with the new requirements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers Deferral of the Effective Date, which deferred the effective date resulting in a new effective date of January 1, 2018 for us. We are permitted to adopt early but not before the original effective date of January 1, 2017. FASB has issued several other ASU's which provide further guidance on Topic 606 and have the same effective date. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. We are currently evaluating the transition method and the adoption date that will be elected. We will implement ASU 2014-09 and all relevant subsequently issued ASU's on Topic 606 concurrently.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments (Tables)
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurement
The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at June 30, 2016 and December 31, 2015.

 
June 30, 2016
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
36,121

$
1,398

$
—

$
37,519

Investments:
 
 
 
 
Certificates of deposit
6,028

—

—

6,028

US Treasury securities
15,822

—

—

15,822

US Agency securities
—

4,010

—

4,010

Commercial Paper
—

499

—

499

Asset-backed securities
—

7,095

—

7,095

Corporate notes and bonds
—

31,465

—

31,465

Total investments
21,850

43,069

—

64,919

Total assets measured at fair value
$
57,971

$
44,467

$
—

$
102,438


 
December 31, 2015
 
(in thousands)
 
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)  
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
 

 

 

 

Cash and cash equivalents
$
120,585

$
—

$
—

$
120,585

Investments:
 
 
 
 
Asset-backed securities
—

2,507

—

2,507

Corporate notes and bonds
—

9,332

—

9,332

Total investments
—

11,839

—

11,839

Total assets measured at fair value
$
120,585

$
11,839

$
—

$
132,424
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Investments (Tables)
 6 Months Ended
Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Investments
The following tables summarize the Company’s available-for-sale investments at June 30, 2016 and December 31, 2015:

AVAILABLE-FOR-SALE INVESTMENTS
June 30, 2016
(in thousands)
 
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Certificates of deposit
$
6,028

$
—

$
—

$
6,028

US Treasury securities
15,780

42

—

15,822

US Agency securities
4,009

1

—

4,010

Commercial paper
499

—

—

499

Asset-backed securities
7,084

11

—

7,095

Corporate notes and bonds
31,449

27

(11
)
31,465

Total
$
64,849

$
81

$
(11
)
$
64,919


AVAILABLE-FOR-SALE INVESTMENTS
December 31, 2015
(in thousands)
 
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Asset-backed securities
$
2,510

$
—

$
(3
)
$
2,507

Corporate notes and bonds
9,341

1

(10
)
9,332

Total
$
11,851

$
1

$
(13
)
$
11,839
Schedule of Available-For-Sale Investment Maturities
The following table summarizes the maturities of the Company’s available-for-sale securities at June 30, 2016 and December 31, 2015:

AVAILABLE-FOR-SALE INVESTMENT MATURITIES
(in thousands)
 
June 30, 2016
December 31, 2015
 
Amortized
Cost
Fair Value
Amortized
Cost
Fair Value
Due in less than 1 year
$
27,517

$
27,535

$
11,851

$
11,839

Due in 1-5 years
37,332

37,384

—

—

Due in 6-10 years
—

—

—

—

Total
$
64,849

$
64,919

$
11,851

$
11,839
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Tables)
 6 Months Ended
Jun. 30, 2016
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment are recorded at cost and consisted of the following at June 30, 2016 and December 31, 2015.
 
PROPERTY AND EQUIPMENT
(in thousands)
 
June 30,
December 31,
 
2016
2015
Computer equipment
$
2,173

$
1,877

Technical equipment
2,329

1,806

Facilities
3,491

1,772

Capital projects in progress
736

2,183

Total property and equipment
$
8,729

$
7,638

Accumulated depreciation - other
(3,769
)
(2,622
)
Net property and equipment
$
4,960

$
5,016
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Deferred Revenue and Income (Tables)
 6 Months Ended
Jun. 30, 2016
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue and Income Summary
A summary of the balances as of June 30, 2016 and December 31, 2015 follows:
Deferred Revenue and Income
(in thousands)

June 30,
December 31,

2016
2015
Fisher agreement
$
—

$
13

Products not yet delivered
43

114

Total current deferred revenue and income
$
43

$
127






Arizona Commerce Authority grant
$
1,000

$
1,000

Total long-term deferred income
$
1,000

$
1,000
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Option Activity
The following table summarizes option activity under all plans during the six-month period ending June 30, 2016:

Stock Option Activity
 
Number of Shares
Weighted Average Exercise Price per Share
Options outstanding January 1, 2016
6,167,170

6.91

Granted
899,600

13.09

Forfeited
(119,706
)
20.06

Exercised
(27,233
)
3.49

Expired
(1,789
)
13.49

Options Outstanding June 30, 2016
6,918,042

7.49
Black-Scholes Assumptions for Options Granted
The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for during the periods shown below:

Black-Scholes Assumptions for Options Granted
 
Three Months Ended
 
June 30, 2016
June 30, 2015
Expected term (in years)
6.2
6.4
Volatility
85%
92%
Expected dividends
—
—
Risk free interest rates
1.45%
1.73%
Weighted average fair value
$9.66
$17.55
Stock Option Supplemental Information
The following table shows summary information for outstanding options, options that are exercisable (vested) and outstanding options that are either vested or expected to vest as of June 30, 2016:

Stock Option Supplemental Information
 
Options
Outstanding
Options
Exercisable
Options Vested and Expected to Vest
Number of options
6,918,042

4,268,778

6,715,032

Weighted average remaining contractual term (in years)
7.06

6.41

7.00

Weighted average exercise price
$
7.49

$
5.01

$
7.28

Weighted average fair value
$
5.80

$
3.77

$
5.63

Aggregate intrinsic value (in thousands)
$
37,775

$
34,813

$
38,171
Restricted Stock Unit (RSU) Activity
The following table summarizes restricted stock unit activity during the six-month period ending June 30, 2016:

Restricted Stock Unit (RSU) Activity
 
Number of Shares
Weighted Average Grant Date Fair Value per Share
RSUs Outstanding January 1, 2016
40,250

20.91

Granted
—

—

Forfeited
—

—

Vested/released
—

—

RSUs outstanding June 30, 2016
40,250

20.91
Equity-Based Compensation Expenses
The expense recognized on Company’s Statements of Operations and Comprehensive Loss related to options is summarized below:

Equity-Based Compensation Expenses
(in thousands)
 
Three Months Ended
Six Months Ended
 
6/30/2016
6/30/2015
6/30/2016
6/30/2015
Research and development
$
462

$
747

$
664

$
1,435

Sales, general and administrative
1,773

1,781

3,257

2,750

Equity-based compensation expense
$
2,235

$
2,528

$
3,921

$
4,185
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments (Tables)
 6 Months Ended
Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Operating Leases Obligations
Future minimum lease payments under operating lease agreements are as follows:

Operating Lease Obligations
(in thousands)
Year ending December 31:
 
2016
$
498

2017
173

2018
4

2019
—

Thereafter
—

Total operating lease obligations
$
675
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value $ 102,438 $ 132,424
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 57,971 120,585
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 44,467 11,839
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Cash and cash equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 37,519 120,585
Cash and cash equivalents | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 36,121 120,585
Cash and cash equivalents | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 1,398 0
Cash and cash equivalents | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 6,028  
Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 6,028  
Certificates of deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
US Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 15,822  
US Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 15,822  
US Treasury securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
US Treasury securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
US Agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 4,010  
US Agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
US Agency securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 4,010  
US Agency securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 499  
Commercial Paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
Commercial Paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 499  
Commercial Paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0  
Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 7,095 2,507
Asset-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Asset-backed securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 7,095 2,507
Asset-backed securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 31,465 9,332
Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Corporate notes and bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 31,465 9,332
Corporate notes and bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 0 0
Total investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 64,919 11,839
Total investments | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 21,850 0
Total investments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value 43,069 11,839
Total investments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets measured at fair value $ 0 $ 0
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Credit Risk (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Concentration Risk [Line Items]      
Trade accounts receivable $ 169   $ 77
Cash and cash equivalents | Concentration of Credit Risk      
Concentration Risk [Line Items]      
Risk concentration (percent) 70.00%   100.00%
Accounts receivable | Customer Concentration Risk | Denver Health      
Concentration Risk [Line Items]      
Risk concentration (percent) 76.00%   66.00%
Trade accounts receivable $ 129   $ 50
Revenue from product sales | Customer Concentration Risk | Denver Health      
Concentration Risk [Line Items]      
Risk concentration (percent) 100.00% 0.00%  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Investments - Schedule of Available-for-sale Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Investment [Line Items]    
Amortized Cost $ 64,849 $ 11,851
Gross Unrealized Gains 81 1
Gross Unrealized Losses (11) (13)
Fair Value 64,919 11,839
Certificates of deposit    
Investment [Line Items]    
Amortized Cost 6,028  
Gross Unrealized Gains 0  
Gross Unrealized Losses 0  
Fair Value 6,028  
US Treasury securities    
Investment [Line Items]    
Amortized Cost 15,780  
Gross Unrealized Gains 42  
Gross Unrealized Losses 0  
Fair Value 15,822  
US Agency securities    
Investment [Line Items]    
Amortized Cost 4,009  
Gross Unrealized Gains 1  
Gross Unrealized Losses 0  
Fair Value 4,010  
Commercial Paper    
Investment [Line Items]    
Amortized Cost 499  
Gross Unrealized Gains 0  
Gross Unrealized Losses 0  
Fair Value 499  
Asset-backed securities    
Investment [Line Items]    
Amortized Cost 7,084 2,510
Gross Unrealized Gains 11 0
Gross Unrealized Losses 0 (3)
Fair Value 7,095 2,507
Corporate notes and bonds    
Investment [Line Items]    
Amortized Cost 31,449 9,341
Gross Unrealized Gains 27 1
Gross Unrealized Losses (11) (10)
Fair Value $ 31,465 $ 9,332
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Investments - Schedule of Available-For-Sale Investment Maturities (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Amortized Cost    
Due in less than 1 year $ 27,517 $ 11,851
Due in 1-5 years 37,332 0
Due in 6-10 years 0 0
Total 64,849 11,851
Fair Value    
Due in less than 1 year 27,535 11,839
Due in 1-5 years 37,384 0
Due in 6-10 years 0 0
Total $ 64,919 $ 11,839
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Investments - Narrative (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Investments, Debt and Equity Securities [Abstract]        
Proceeds from sales of marketable securities $ 500,000 $ 34,000 $ 1,000,000 $ 141,000
Gross realized gains or losses from sales of marketable securities $ 0 $ 0 $ 0 $ 0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Property, Plant and Equipment [Line Items]          
Property and equipment $ 8,729   $ 8,729   $ 7,638
Accumulated depreciation - other (3,769)   (3,769)   (2,622)
Net property and equipment 4,960   4,960   5,016
Depreciation 605 $ 403 1,147 $ 729  
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 2,173   2,173   1,877
Technical equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 2,329   2,329   1,806
Facilities          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,491   3,491   1,772
Capital projects in progress          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 736   $ 736   $ 2,183
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
License Agreements and Grants - Defense Medical Research and Development Program (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 50 Months Ended
May 31, 2012
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Offset to research and development project   $ 0 $ 0 $ 1,200,000 $ 647,000  
Defense medical research and development program            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Total grant funding $ 2,000,000          
Length of project (months) 35 months          
Offset to research and development project   $ 44,000 $ 68,000 $ 44,000 $ 136,000 $ 602,000
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
License Agreements and Grants - National Institute of Health Grant (Details) - National Institute of Health Grant - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 28, 2015
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Jan. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Length of project (years) 5 years          
Total grant funding $ 5,000 $ 50 $ 0 $ 59 $ 0 $ 689
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2012
USD ($)
job
milestone
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
License Agreements and Grants - Research and Development [Abstract]            
Arizona Commerce Authority grant | $ $ 1,000,000.0 $ 1,000,000.0   $ 1,000,000.0   $ 1,000,000
Number of milestones | milestone 4          
Qualified jobs created, milestone one | job 15          
Qualified jobs created, milestone two | job 30          
Qualified jobs created, milestone three | job 40          
Qualified jobs created, milestone four | job 65          
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Offset to research and development project | $   $ 0 $ 0 $ 1,200,000 $ 647,000  
Minimum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Capital investment milestone | $ $ 4,500,000          
Grant related minimum annual wages | $ $ 63,000          
Percent of company paid premiums 65.00%          
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Deferred Revenue and Income (Details) - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Aug. 31, 2012
Deferred Revenue Disclosure [Abstract]      
Fisher agreement $ 0 $ 13,000  
Products not yet delivered 43,000 114,000  
Total current deferred revenue and income 43,000 127,000  
Arizona Commerce Authority grant 1,000,000.0 1,000,000 $ 1,000,000.0
Total long-term deferred income $ 1,000,000 $ 1,000,000  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings Per Share (Details) - shares
 6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Earnings Per Share [Abstract]    
Antidilutive common stock instruments outstanding (shares) 7,529,452 6,778,580
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details)
 6 Months Ended
Jun. 30, 2016
$ / shares
shares
Number of Shares  
Outstanding, beginning balance (shares) | shares 6,167,170
Granted (shares) | shares 899,600
Forfeited (shares) | shares (119,706)
Exercised (shares) | shares (27,233)
Expired (shares) | shares (1,789)
Outstanding, ending balance (shares) | shares 6,918,042
Weighted Average Exercise Price Per Share  
Outstanding, beginning balance (dollars per share) | $ / shares $ 6.91
Granted (dollars per share) | $ / shares 13.09
Forfeited (dollars per share) | $ / shares 20.06
Exercised (dollars per share) | $ / shares 3.49
Expired (dollars per share) | $ / shares 13.49
Outstanding, ending balance (dollars per share) | $ / shares $ 7.49
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details) - USD ($)
 3 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Expected term (in years) 6 years 2 months 12 days 6 years 4 months 24 days
Volatility (percent) 85.00% 92.00%
Expected dividends $ 0 $ 0
Risk free interest rates (percent) 1.45% 1.73%
Fair value per share (dollars per share) $ 9.66 $ 17.55
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 30, 2016
USD ($)
$ / shares
shares
Options Outstanding  
Option Indexed to Issuer's Equity [Line Items]  
Number of options (shares) | shares 6,918,042
Weighted average remaining contractual term (in years) 7 years 22 days
Weighted average exercise price (dollars per share) $ 7.49
Weighted average fair value (dollars per share) $ 5.80
Aggregate intrinsic value (in thousands) | $ $ 37,775
Options Exercisable  
Option Indexed to Issuer's Equity [Line Items]  
Number of options (shares) | shares 4,268,778
Weighted average remaining contractual term (in years) 6 years 4 months 28 days
Weighted average exercise price (dollars per share) $ 5.01
Weighted average fair value (dollars per share) $ 3.77
Aggregate intrinsic value (in thousands) | $ $ 34,813
Options Vested and Expected to Vest  
Option Indexed to Issuer's Equity [Line Items]  
Number of options (shares) | shares 6,715,032
Weighted average remaining contractual term (in years) 7 years
Weighted average exercise price (dollars per share) $ 7.28
Weighted average fair value (dollars per share) $ 5.63
Aggregate intrinsic value (in thousands) | $ $ 38,171
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs)
 6 Months Ended
Jun. 30, 2016
$ / shares
shares
Number of Shares  
Restricted Stock Outstanding, beginning balance (shares) | shares 40,250
Granted (shares) | shares 0
Forfeited (shares) | shares 0
Vested/Released (shares) | shares 0
Restricted Stock Outstanding, ending balance (shares) | shares 40,250
Weighted Average Grant Date Fair Value per Share  
Restricted Stock Outstanding, beginning balance (dollars per share) | $ / shares $ 20.91
Granted (dollars per share) | $ / shares 0.00
Forfeited (dollars per share) | $ / shares 0.00
Vested/Released (dollars per share) | $ / shares 0.00
Restricted Stock Outstanding, ending balance (dollars per share) | $ / shares $ 20.91
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Equity-based compensation expense $ 2,235 $ 2,528 $ 3,921 $ 4,185
Unrecognized equity-based compensation cost 12,400   12,400  
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Equity-based compensation expense 462 747 664 1,435
Sales, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Equity-based compensation expense 1,773 $ 1,781 3,257 $ 2,750
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Unrecognized equity-based compensation cost, restricted stock units $ 482   $ 482  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments - Narrative (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]        
Rent expense $ 280,000 $ 167,000 $ 540,000 $ 282,000
Research and development        
Product Liability Contingency [Line Items]        
Clinical trial expense $ 760,000 $ 178,000 $ 1,424,000 $ 358,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments - Operating Lease Obligations (Details)
$ in Thousands
Jun. 30, 2016
USD ($)
Year ending December 31:  
2016 $ 498
2017 173
2018 4
2019 0
Thereafter 0
Total operating lease obligations $ 675
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segments (Details)
 6 Months Ended
Jun. 30, 2016
segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions (Details)
 1 Months Ended
Jun. 30, 2016
USD ($)
Recovery of short-swing profit  
Related Party Transaction [Line Items]  
Recovery of related party short-swing profits $ 866,000
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 113 191 1 false 31 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://acceleratediagnostics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://acceleratediagnostics.com/role/CondensedConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://acceleratediagnostics.com/role/CondensedConsolidatedBalanceSheetParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://acceleratediagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 1004000 - Statement - CONDENSED CONSOLIDATEDSTATEMENT OF CASH FLOWS Sheet http://acceleratediagnostics.com/role/CondensedConsolidatedstatementOfCashFlows CONDENSED CONSOLIDATEDSTATEMENT OF CASH FLOWS Statements 5 false false R6.htm 2101100 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Sheet http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidationSignificantAccountingPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Notes 6 false false R7.htm 2102100 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 7 false false R8.htm 2103100 - Disclosure - Fair Value of Financial Instruments Sheet http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 8 false false R9.htm 2104100 - Disclosure - Concentration of Credit Risk Sheet http://acceleratediagnostics.com/role/ConcentrationOfCreditRisk Concentration of Credit Risk Notes 9 false false R10.htm 2105100 - Disclosure - Investments Sheet http://acceleratediagnostics.com/role/Investments Investments Notes 10 false false R11.htm 2106100 - Disclosure - Property and Equipment Sheet http://acceleratediagnostics.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 2107100 - Disclosure - License Agreements and Grants Sheet http://acceleratediagnostics.com/role/LicenseAgreementsAndGrants License Agreements and Grants Notes 12 false false R13.htm 2108100 - Disclosure - Deferred Revenue and Income Sheet http://acceleratediagnostics.com/role/DeferredRevenueAndIncome Deferred Revenue and Income Notes 13 false false R14.htm 2109100 - Disclosure - Earnings Per Share Sheet http://acceleratediagnostics.com/role/EarningsPerShare Earnings Per Share Notes 14 false false R15.htm 2110100 - Disclosure - Employee and Consultant Equity-Based Compensation Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation Employee and Consultant Equity-Based Compensation Notes 15 false false R16.htm 2112100 - Disclosure - Commitments Sheet http://acceleratediagnostics.com/role/Commitments Commitments Notes 16 false false R17.htm 2113100 - Disclosure - Segments Sheet http://acceleratediagnostics.com/role/Segments Segments Notes 17 false false R18.htm 2114100 - Disclosure - Related Party Transactions Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 2115100 - Disclosure - Subsequent Events Sheet http://acceleratediagnostics.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 2201201 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Sheet http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidationSignificantAccountingPoliciesPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Policies http://acceleratediagnostics.com/role/OrganizationAndNatureOfBusinessBasisOfPresentationPrinciplesOfConsolidationSignificantAccountingPolicies 20 false false R21.htm 2303301 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://acceleratediagnostics.com/role/FairValueOfFinancialInstruments 21 false false R22.htm 2305301 - Disclosure - Investments (Tables) Sheet http://acceleratediagnostics.com/role/InvestmentsTables Investments (Tables) Tables http://acceleratediagnostics.com/role/Investments 22 false false R23.htm 2306301 - Disclosure - Property and Equipment (Tables) Sheet http://acceleratediagnostics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://acceleratediagnostics.com/role/PropertyAndEquipment 23 false false R24.htm 2308301 - Disclosure - Deferred Revenue and Income (Tables) Sheet http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables Deferred Revenue and Income (Tables) Tables http://acceleratediagnostics.com/role/DeferredRevenueAndIncome 24 false false R25.htm 2310301 - Disclosure - Employee and Consultant Equity-Based Compensation (Tables) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationTables Employee and Consultant Equity-Based Compensation (Tables) Tables http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensation 25 false false R26.htm 2312301 - Disclosure - Commitments (Tables) Sheet http://acceleratediagnostics.com/role/CommitmentsTables Commitments (Tables) Tables http://acceleratediagnostics.com/role/Commitments 26 false false R27.htm 2403402 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://acceleratediagnostics.com/role/FairValueOfFinancialInstrumentsTables 27 false false R28.htm 2404401 - Disclosure - Concentration of Credit Risk (Details) Sheet http://acceleratediagnostics.com/role/ConcentrationOfCreditRiskDetails Concentration of Credit Risk (Details) Details http://acceleratediagnostics.com/role/ConcentrationOfCreditRisk 28 false false R29.htm 2405402 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleOfAvailableForSaleSecuritiesDetails Investments - Schedule of Available-for-sale Securities (Details) Details 29 false false R30.htm 2405403 - Disclosure - Investments - Schedule of Available-For-Sale Investment Maturities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleOfAvailableForSaleInvestmentMaturitiesDetails Investments - Schedule of Available-For-Sale Investment Maturities (Details) Details 30 false false R31.htm 2405404 - Disclosure - Investments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 31 false false R32.htm 2406402 - Disclosure - Property and Equipment (Details) Sheet http://acceleratediagnostics.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://acceleratediagnostics.com/role/PropertyAndEquipmentTables 32 false false R33.htm 2407401 - Disclosure - License Agreements and Grants - Defense Medical Research and Development Program (Details) Sheet http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsDefenseMedicalResearchAndDevelopmentProgramDetails License Agreements and Grants - Defense Medical Research and Development Program (Details) Details 33 false false R34.htm 2407402 - Disclosure - License Agreements and Grants - National Institute of Health Grant (Details) Sheet http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsNationalInstituteOfHealthGrantDetails License Agreements and Grants - National Institute of Health Grant (Details) Details 34 false false R35.htm 2407403 - Disclosure - License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details) Sheet http://acceleratediagnostics.com/role/LicenseAgreementsAndGrantsArizonaCommerceAuthorityAndRdRefundableTaxCreditProgramDetails License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details) Details 35 false false R36.htm 2408402 - Disclosure - Deferred Revenue and Income (Details) Sheet http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeDetails Deferred Revenue and Income (Details) Details http://acceleratediagnostics.com/role/DeferredRevenueAndIncomeTables 36 false false R37.htm 2409401 - Disclosure - Earnings Per Share (Details) Sheet http://acceleratediagnostics.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://acceleratediagnostics.com/role/EarningsPerShare 37 false false R38.htm 2410402 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionActivityDetails Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details) Details 38 false false R39.htm 2410403 - Disclosure - Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationBlackScholesAssumptionsForOptionGrantedDetails Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details) Details 39 false false R40.htm 2410404 - Disclosure - Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationStockOptionSupplementalInformationDetails Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details) Details 40 false false R41.htm 2410405 - Disclosure - Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationRestrictedStockActivityDetails Employee and Consultant Equity-Based Compensation - Restricted Stock Activity (Details) Details 41 false false R42.htm 2410406 - Disclosure - Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) Sheet http://acceleratediagnostics.com/role/EmployeeAndConsultantEquityBasedCompensationEquityBasedCompensationExpenseAndTaxBenefitDetails Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) Details 42 false false R43.htm 2412402 - Disclosure - Commitments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/CommitmentsNarrativeDetails Commitments - Narrative (Details) Details 43 false false R44.htm 2412403 - Disclosure - Commitments - Operating Lease Obligations (Details) Sheet http://acceleratediagnostics.com/role/CommitmentsOperatingLeaseObligationsDetails Commitments - Operating Lease Obligations (Details) Details 44 false false R45.htm 2413401 - Disclosure - Segments (Details) Sheet http://acceleratediagnostics.com/role/SegmentsDetails Segments (Details) Details http://acceleratediagnostics.com/role/Segments 45 false false R46.htm 2414401 - Disclosure - Related Party Transactions (Details) Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://acceleratediagnostics.com/role/RelatedPartyTransactions 46 false false All Reports Book All Reports axdx-20160630.xml axdx-20160630.xsd axdx-20160630_cal.xml axdx-20160630_def.xml axdx-20160630_lab.xml axdx-20160630_pre.xml true true ZIP 63 0001628280-16-018725-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-16-018725-xbrl.zip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͋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end